https://trial.medpath.com/news/04e6ba3498422d58/xoma-royalty-acquires-pulmokine-for-20m-adds-phase-3-pah-drug-to-portfolio 2024-12-02T12:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/4e415545f65073a0/hybrytetm-clinical-results-demonstrate-continued-improvement-post-treatment-pr-newswire 2024-12-02T12:37:15+00:00 weekly 0.7 https://trial.medpath.com/news/423692b17c6da8ef/medexus-amends-treosulfan-deal-100m-revenue-target-fda-milestone-payments-up-to-45m 2024-12-02T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/06a61103f4bc113f/olema-oncology-lands-250m-funding-novartis-partnership-for-cancer-drug-trial 2024-12-02T12:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/61626307ca318f49/revelation-biosciences-inc-announces-fda-acceptance-of-gemini-ind-stock-titan 2024-12-02T11:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/c6838bb90c5b8db0/molecular-testing-drives-personalized-treatment-approaches-in-endometrial-cancer 2024-12-02T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/250d64ec3de9e22b/breakthrough-hiv-cure-trial-targets-women-in-kzn-the-witness 2024-12-02T10:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/cb523365f4c4a638/a-feasibility-study-using-quantitative-and-interpretable-histological-analyses-of-celiac-disease 2024-12-02T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/551f559bba115db5/medicare-s-first-drug-price-negotiations-yield-mixed-results-u-s-prices-still-exceed-international-levels 2024-12-02T08:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/78424ebbfdf313a6/interactions-with-uk-regulatory-authorities-faron-pharmaceuticals-oy-cision-news 2024-12-02T08:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/13940d0d31d74692/capsule-sponge-test-revolutionizes-gerd-diagnosis-reduces-unnecessary-endoscopies 2024-12-02T07:34:02+00:00 weekly 0.7 https://trial.medpath.com/news/fd3dc9d87b75d7cc/global-biotechnology-market-projected-to-reach-usd-3-54-trillion-by-2033-driven-by-therapeutic-innovations 2024-12-02T07:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/edb0cc7ac6b476be/deepull-receives-fda-breakthrough-device-designation-for-its-ullcore-bloodstream-infection-test 2024-12-02T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/83098e6e3e323870/aavantgarde-bio-announces-fda-orphan-drug-designation-for-globenewswire 2024-12-02T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/308871821825aee7/sparsentan-receives-orphan-drug-designation-for-primary-iga-nephropathy-in-japan 2024-12-02T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/da5d34a456711b78/nicox-s-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china-earlier-than-expected 2024-12-02T06:39:43+00:00 weekly 0.7 https://trial.medpath.com/news/162623e547a52844/hk-inno-n-s-gerd-drug-k-cab-recommended-for-approval-in-india-kbr 2024-12-02T05:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/a80920bb65ef920a/orum-therapeutics-withdraws-from-ipo-citing-difficulties-in-fair-valuation-kbr 2024-12-02T02:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/6315eda8c8747c7f/preliminary-adaptation-of-cognitive-behavioral-therapy-for-major-depression-in-bmc-psychiatry 2024-12-02T02:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/be7f7ab1ff531f94/effect-of-fecal-microbiota-transplantation-on-patients-with-sporadic-amyotrophic-lateral-sclerosis 2024-12-02T02:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/efa82c1b7b3f3bfe/quabodepistat-combo-shows-promise-for-safer-faster-tuberculosis-treatment-news-medical 2024-12-02T00:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/064816bd264917ae/home-sapience-therapeutics 2024-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0d7ce8989ab008ec/why-this-asx-healthcare-share-is-soaring-26-on-study-findings-motley-fool 2024-12-01T23:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/12a555575bf0e0f4/everest-medicines-announces-acceptance-of-velsipity-r-new-drug-application-in-hong-kong 2024-12-01T23:44:01+00:00 weekly 0.7 https://trial.medpath.com/news/b1d2bf5821f4f136/orthocell-ever-closer-to-us-remplirtm-launch-as-it-wraps-up-regulatory-study-for-fda-clearance 2024-12-01T23:23:05+00:00 weekly 0.7 https://trial.medpath.com/news/02bbd377a8742787/clinical-study-in-hk-confirms-singapore-s-bixeps-machine-improves-muscle-strength 2024-12-01T21:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/8c4e2339bcde40bc/ongoing-clinical-trial-shows-very-promising-results-using-eye-implant-to-treat-macular 2024-12-01T20:51:04+00:00 weekly 0.7 https://trial.medpath.com/news/aa9b08ef06e44d2c/endocrinology-month-in-review-november-2024-hcplive 2024-12-01T20:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/d22775d1f063378b/evaluating-covid-19-vaccination-safety-in-multiple-sclerosis 2024-12-01T19:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/26a8af5559d8457f/dangerous-food-allergy-reactions-a-drug-free-life 2024-12-01T19:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/e8f3196b65e2fcdc/higher-dose-of-nusinersen-shows-greater-impact-on-spinal-muscular-atrophy-in-phase-2-3 2024-12-01T17:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/648643f68d7cd888/merus-s-petosemtamab-shows-40-4-response-rate-in-head-neck-cancer-trial 2024-12-01T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/539303d8fd9c637b/hepb-cpg-vs-hepb-alum-vaccine-in-people-with-hiv-and-prior-vaccine-nonresponse 2024-12-01T16:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/0a2532e11c4f9e41/fda-permits-using-johnson-johnson-cancer-drug-without-chemo 2024-12-01T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/d92c568394b76c08/jazz-pharmaceuticals-jazz-is-making-sweet-music-with-a-diverse-portfolio-tipranks 2024-12-01T15:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/bf1ba8cadb21eab6/lactated-ringer-s-a-clear-winner-for-pancreatitis-resuscitation-emergency-medicine-news 2024-12-01T15:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/f9e139531ef3e923/drug-topics-top-10-most-read-stories-from-november-2024 2024-12-01T15:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/2739a5ed39d2cc9d/sidra-medicine-conducts-first-clinical-trial-for-pediatric-congenital-hyperinsulinism 2024-12-01T13:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/aa9c856ebce8fbd8/new-diabetes-treatment-delays-onset-of-type-1-diabetes-uh-treats-first-ne-ohio-patient 2024-12-01T12:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/de6cefeeea03eef2/aasm-updates-restless-legs-syndrome-treatment-guidelines-shifts-away-from-dopamine-agonists 2024-12-01T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8dbb369b22ecd288/aav-delivery-strategy-with-mechanical-support-for-safe-and-efficacious-cardiac-gene-transfer-in-swine 2024-12-01T09:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/84c6e77d73f6da2c/a-twice-yearly-shot-could-help-end-aids-bangladesh-unb 2024-12-01T09:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/2038400b588cd64f/u-s-fda-approves-biocon-biologics-yesintektm-bmab-1200-biosimilar-to-j-j-s-stelara 2024-12-01T08:57:04+00:00 weekly 0.7 https://trial.medpath.com/news/b4cb6ef3f95b3289/breakthrough-hiv-prevention-shot-faces-global-access-challenges-health-devdiscourse 2024-12-01T06:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/d8ea8504aa93c71c/2025-trends-buoying-boom-phase-in-apac-biospectrum-asia 2024-12-01T05:24:18+00:00 weekly 0.7 https://trial.medpath.com/news/facc6e4d1d5d4a0e/kidney-failure-was-the-third-fastest-growing-cause-of-death-in-2023-exacerbated-by-the-lack 2024-12-01T05:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/f513d0e33f6cd6c5/graft-versus-host-disease-pipeline-therapeutics-assessment-report-2024-updated-openpr-com 2024-12-01T05:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/ff37b23c912cdebe/hiv-prevention-remains-elusive-biospectrum-india 2024-12-01T02:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/2e5b2b9a7f76032e/zydus-cadila-begins-enrolment-for-phase-3-vaccine-trial-reports-inshorts 2024-12-01T02:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/b19c2d5122c2d15b/moderna-inc-mrna-a-bull-case-theory-yahoo-finance 2024-12-01T00:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/e7d89733ce375a57/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c4ad5f341a4fa2b/prevalence-and-profiles-of-treatment-related-adverse-events-in-metastatic-breast-cancer-patients-receiving-antibody-drug-conjugates 2024-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0040dfc14cf1a5a9/praxis-precision-medicines-to-showcase-updates-from-pipeline-of-epilepsy-pharmabiz-com 2024-11-30T23:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/4d39f0fa89104d5f/arvin-k-george-md-provides-update-on-the-preserve-trial-urology-times 2024-11-30T23:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/5e1333c5a0e9f0b9/vcu-startup-grabs-military-attention-funding-virginia-business 2024-11-30T21:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/1f443131f2b297c3/applied-therapeutics-crl-a-major-setback-says-william-blair-yahoo-finance 2024-11-30T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/14470b09df2e83c2/an-introduction-to-ananda-developments-share-talk 2024-11-30T20:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/6c8ef097306f2bbf/trem-1-and-trem-2-as-therapeutic-targets-clinical-challenges-and-perspectives 2024-11-30T19:54:52+00:00 weekly 0.7 https://trial.medpath.com/news/bafcdbbbd698fa3b/zai-lab-announces-the-inclusion-of-augtyro-for-ros1-nsclc-and-other-updates-in-china-s 2024-11-30T19:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/9149e8500bf8d007/hua-medicine-announces-successful-u-s-phase-i-results-on-its-2nd-generation-gka-candidate 2024-11-30T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/b14c283ec9cbf89b/effectiveness-of-photobiomodulation-with-low-level-lasers-on-the-acceleration-of-orthodontic 2024-11-30T19:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/a177f3c6f902310c/medical-breakthrough-or-temporary-fix-the-brutal-truth-about-weight-loss-medications 2024-11-30T19:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/dc43d2bf5e38ce7e/phase-2-galactic53-data-point-to-viltolarsen-s-impact-on-respiratory-and-motor-function-in-dmd 2024-11-30T16:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/d206bbbf1bd65213/deuruxolitinib-demonstrates-efficacy-safety-in-adults-with-alopecia-areata 2024-11-30T16:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/ca93b6bf949f27aa/new-cpx-351-data-underscore-complexity-of-treating-aml-in-older-patients 2024-11-30T16:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/388f084bb2d176a0/b-c-man-calls-for-federal-government-to-cover-costly-life-saving-cancer-treatment-cbc 2024-11-30T15:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/2d1665e8fa112712/first-patient-dosed-in-study-assessing-immunotherapy-in-metastatic-breast-cancer 2024-11-30T15:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/00b4b83172e8d4c8/india-takes-centre-stage-in-clinical-trials-for-hiv-aids-drug-drugscontrol-media-services 2024-11-30T14:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/bd09e203bf861699/how-a-landmark-uc-davis-health-clinical-trial-to-treat-spina-bifida-gave-one-roseville-family-hope 2024-11-30T13:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/9887ae9369068697/biotech-stock-roundup-bbio-stock-up-on-drug-approval-sava-aplt-plunge-on-setbacks-more 2024-11-30T13:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/84af3650d6a8052a/hua-medicine-announces-successful-h-k-sensitize-study-results-at-the-cbiic 2024-11-30T12:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/e6cda030a2ad7895/warning-this-skyrocketing-stock-has-a-hidden-risk-the-globe-and-mail 2024-11-30T11:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/7b8cc26c63e20864/chronic-hand-eczema-november-2024-supplement-recap-dermatology-times 2024-11-30T11:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/298cbd650800bc58/i-m-a-dementia-expert-who-spent-25-years-caring-for-patients-now-i-ve-been-diagnosed 2024-11-30T11:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/825cdf9a16196e0b/ucla-researchers-engineer-experimental-drug-for-preventing-heart-failure-after-heart-attacks 2024-11-30T11:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/a4b9e02f8c2b6576/oragenics-announces-termination-of-president-s-employment-agreement-investing-com 2024-11-30T09:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/a4da634b46e6cbb6/lumosa-therapeutics-co-ltd-announces-the-unblinded-analysis-results-from-phase-ii 2024-11-30T07:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/c531978e0940c6fb/bcma-car-t-therapy-combined-with-pomalidomide-is-a-safe-and-effective-treatment-for 2024-11-30T07:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/dbf6d3e34dccae52/bevacizumab-versus-aflibercept-with-folfiri-after-folfox-and-bevacizumab-in-ras-nature 2024-11-30T07:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/84dc322a00951d2f/q-a-pharmacist-on-medication-developments-for-people-living-with-hiv-drug-topics 2024-11-30T06:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/7d1686acc4eca364/global-cancer-care-crisis-study-reveals-widening-treatment-access-gap-between-rich-and-poor-nations 2024-11-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/763c41cf3fce0441/concizumab-reduces-bleeding-in-patients-without-inhibitors-hemophilia-news-today 2024-11-30T05:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/1596eb2e8479b30e/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc 2024-11-30T04:04:52+00:00 weekly 0.7 https://trial.medpath.com/news/aeb5c5209d81dec3/new-ppar-agonists-expand-treatment-landscape-for-primary-biliary-cholangitis 2024-11-30T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75a4df3a21dbf5f0/mirum-plans-2025-phase-2-trial-testing-fragile-x-treatment 2024-11-29T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/87f509cd17564a76/navitoclax-and-ruxolitinib-show-potential-in-treating-r-r-myelofibrosis-pharmacy-times 2024-11-29T21:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/da93f88b52134b16/effectiveness-of-probiotics-prebiotics-and-synbiotics-in-managing-insulin-resistance-pubmed 2024-11-29T20:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/166c657eb4ae8053/neurologylive-r-friday-5-november-29-2024 2024-11-29T20:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/240214ae8cb6c3b7/medmira-reports-fy2024-fourth-quarter-and-year-end-financial-results-biospace 2024-11-29T18:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/a72bed31e5330b30/apogee-therapeutics-announces-agenda-for-virtual-r-d-day-morningstar 2024-11-29T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/ad867352beb73d6e/polypid-announces-receipt-of-nasdaq-notification-of-minimum-globenewswire 2024-11-29T18:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/d54c29eb6f74913d/biotech-raises-11m-to-advance-regenerative-osteoarthritis-drug-into-phase-3 2024-11-29T17:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/04abd83fbe2edcac/mushroom-drug-statistics-2024-by-best-compound-market-us-media 2024-11-29T17:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/9d525f1c97198ca1/jssstu-and-in-space-launch-jnanam-student-satellite-project-mysuru-news 2024-11-29T17:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/a5108bde5d099917/fda-clears-dr-betz-s-vertebral-body-replacement-device-orthopedics-this-week 2024-11-29T17:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/ae2cf931e1bc65a1/high-cholesterol-linked-to-ms-cognitive-impairment-in-study-multiple-sclerosis-news-today 2024-11-29T15:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/0165e6f309f2b508/medtronic-reports-outcomes-from-aortic-stenosis-treatment-study-of-tavr-system 2024-11-29T15:47:29+00:00 weekly 0.7 https://trial.medpath.com/news/e082bec2968eebef/association-between-red-cell-distribution-width-and-30-day-mortality-in-patients-with-frontiers 2024-11-29T15:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/5bdb031029a6c9bb/advent-of-ponatinib-for-ph-all-expected-to-influence-new-guidelines 2024-11-29T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/91595a2456130299/cell-therapy-weekly-first-patient-dosed-in-cardiac-gene-therapy-trial-regmednet 2024-11-29T15:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/f8d74c3cb6739360/epi-pen-alternative-now-available-in-the-mid-state-wsmv 2024-11-29T14:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/85db07cea4e77dfb/uk-s-clinical-trials-diversity-draft-gets-over-200-stakeholder-responses 2024-11-29T14:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/327d4b05ae8ab5d4/when-the-body-attacks-itself-cu-anschutz-medical-campus 2024-11-29T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/347c049af4f8a521/elacestrant-shows-significant-pfs-benefit-in-esr1-mutated-metastatic-breast-cancer 2024-11-29T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/fcfda1d177951d48/vznkul-nmibc-quality-indicators-program-a-flemish-prospective-cohort-to-evaluate-the 2024-11-29T14:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/91068d42d7b4c56b/micurx-successfully-completes-phase-iii-clinical-trial-of-mrx-4-for-injection-in-china 2024-11-29T14:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/e3b9c6b7d000fc67/mathematical-modeling-framework-enhances-clinical-trial-design-for-maintenance-treatment 2024-11-29T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/04cc1974cfab4ceb/scientists-identify-drug-resistant-bone-marrow-cells-linked-to-poor-outcomes-in-fast-growing-leukemia 2024-11-29T13:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/900d40948ac0c17a/coventry-hospital-in-world-first-cancer-scanner-trial-bbc 2024-11-29T13:43:37+00:00 weekly 0.7 https://trial.medpath.com/news/625b070bb70df191/nuhcs-to-start-using-breakthrough-drug-for-rare-lung-condition-healthcare-asia-magazine 2024-11-29T13:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/23a9b2a3753821e0/mirikizumab-effective-in-crohn-s-disease-after-initial-standard-therapy-failure 2024-11-29T13:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/693b9b32a8a2bab8/minghui-pharmaceutical-announces-positive-topline-results-from-phase-iii-trial-of-mh004 2024-11-29T13:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/859e4389e027c1f7/china-focus-weight-loss-drug-a-new-option-to-combat-obesity-in-china-xinhua 2024-11-29T13:29:47+00:00 weekly 0.7 https://trial.medpath.com/news/5f9b89883f3a59d9/nanozymes-unlocking-next-generation-anti-inflammatory-treatments-nature 2024-11-29T13:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/56682248afef2ec2/vabysmo-hopes-to-ride-new-coverage-in-china-data-to-expand-in-asia-citeline 2024-11-29T13:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/74ae2c0a28a54e22/takeda-canada-co-sponsors-grant-to-boost-ibd-clinical-research-yahoo-finance 2024-11-29T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/a0ff5d446417f531/3-penny-stocks-ready-to-break-out-in-2025-entrepreneur 2024-11-29T13:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/f01f11864beebf61/silo-pharma-partners-with-kymanox-to-develop-novel-ketamine-implant-device-stock-titan 2024-11-29T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/a36f1bd3f4992b13/a-new-era-for-pancreatic-cancer-research-royal-free-london-nhs-foundation-trust 2024-11-29T13:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/394fde4b693c8741/abbv-3-healthcare-stocks-leading-the-fight-against-global-diseases-stocknews-com 2024-11-29T12:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/94c43e5fbef7453a/gene-and-cell-therapies-targeting-cns-disorders-treatment-market-2034-the-globe-and-mail 2024-11-29T12:53:34+00:00 weekly 0.7 https://trial.medpath.com/news/7abf7f825e0ee3a7/clinical-trial-spots-preston-man-s-potentially-cancerous-polyp-pharmiweb-com 2024-11-29T12:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/2be6665acafc34a5/hepatic-encephalopathy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-29T12:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/f44610ae3c25bd75/nanexa-ab-phase-i-results-position-nex-22-for-licensing-opportunities-and-a-head-start-placera 2024-11-29T12:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/82c1cb8f7eb532dc/propionic-acid-impact-on-multiple-sclerosis-evidence-and-challenges-pubmed 2024-11-29T12:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/1572205daa08cef6/addyi-sex-drive-pill-for-women-that-s-fda-approved 2024-11-29T11:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/b6efecc58516f649/relapse-in-ocular-tuberculosis-study-reveals-one-third-of-cases-resurface-after-treatment 2024-11-29T11:19:16+00:00 weekly 0.7 https://trial.medpath.com/news/17ff307f0d411426/radnet-s-deephealth-subsidiary-expands-fda-clearance-for-smartmammotm-solution 2024-11-29T11:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/a49566d1eaf3b29a/lupin-gains-tentative-usfda-nod-for-sitagliptin-and-metformin-hydrochloride-tablets 2024-11-29T10:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/44dd0a07ebbb1b7a/sponsored-gi-genius-enters-naiad-large-scale-clinical-trial-health-tech-world 2024-11-29T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/4a81ef3e92e5fae3/real-world-data-and-patient-centered-care-reshape-modern-oncology-treatment-approaches 2024-11-29T10:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/d8540ba5c8bc68b9/kane-biotech-announces-third-quarter-2024-financial-results 2024-11-29T09:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/b98a4fc578408f6d/ananda-aiming-to-meet-regulators-at-their-point-of-need-as-it-secures-more-major-uk 2024-11-29T09:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/6080cc3feab4af97/comprehensive-insight-into-lichen-planus-pipeline-landscape-revealed-for-2024 2024-11-29T09:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/58ced6929ab3fede/limb-girdle-muscular-dystrophy-lgmd-competitive-landscape-report-2024 2024-11-29T09:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/7b644213f7f77e5d/ema-launches-digital-platform-to-combat-drug-shortages-across-european-union 2024-11-29T09:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/54584c8697c85792/china-makes-breakthrough-in-xenotransplantation-with-gene-edited-pig-kidney-surviving 2024-11-29T09:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/a5fc2e1032cfbe51/evidentiary-basis-of-the-first-regulatory-qualification-of-a-digital-primary-efficacy-endpoint 2024-11-29T09:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/8eb50c385aa13e82/study-reveals-10-distinct-cellular-neighborhoods-in-pancreatic-cancer-opening-new-treatment-pathways 2024-11-29T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b63f85646896365f/will-neumora-therapeutics-upcoming-data-catalysts-drive-stock-performance 2024-11-29T08:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/e052b14bb8207e4d/agile-monitoring-dashboard-for-clinical-research-studies-trials-biomed-central 2024-11-29T08:29:26+00:00 weekly 0.7 https://trial.medpath.com/news/36fc20ce7bd46d14/study-links-long-term-tattoo-exposure-to-increased-risk-of-rare-b-cell-lymphomas 2024-11-29T07:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca84048800fac832/lanchi-ventures-leads-42m-series-a-financing-for-allink-biotherapeutics-to-accelerate 2024-11-29T07:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd05e18c6b710987/ochsner-lsu-health-surgeon-successfully-performs-new-procedure-that-marks-a 2024-11-29T06:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/750114eded0ede18/expert-urges-integration-of-novel-therapies-and-patient-education-in-multiple-myeloma-treatment 2024-11-29T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/37d80a726a4cb19c/global-rare-disease-drug-market-sees-promising-growth-amid-complex-access-challenges 2024-11-29T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7830012b5b3b4fb8/uk-launches-historic-national-men-s-health-strategy-to-address-critical-health-disparities 2024-11-29T04:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/cfcbbf74697cc87c/nefecon-r-included-in-national-reimbursement-drug-list-nrdl-jcn-newswire 2024-11-29T04:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/6f5462457de7510e/pharma-stock-in-focus-after-it-launches-india-s-first-neck-head-cancer-treatment-drug 2024-11-29T04:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/e9166f6bf607b850/bharath-advanced-therapeutics-bat-and-faba-present-cancer-next-2024 2024-11-29T03:55:13+00:00 weekly 0.7 https://trial.medpath.com/news/8e901b41fd086b70/revolutionary-pace-system-transforms-clinical-trial-drug-manufacturing-at-cpi-s-innovation-centre 2024-11-29T03:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/d435c87385e5bf8a/do-biosimilar-monoclonal-antibodies-perform-as-well-as-the-original-medicine-for-cancer-treatment 2024-11-29T02:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/7e204f0c60a3aa96/clinical-trial-landscape-for-histone-deacetylation-inhibitors-in-breast-cancer-a-dawn-in-the-darkness 2024-11-29T01:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/9b8ce15d0a4174c7/medytox-secures-thai-fda-approval-for-hyaluronic-acid-filler-atiere-pharma-article-kbr 2024-11-29T01:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/d01234f883f27c4d/cell-therapy-company-just-acquired-by-roche-for-us-1-5bn-ala-looks-similar 2024-11-29T01:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/96586e67b3b738a0/real-world-data-demonstrate-efficacy-of-beti-cel-gene-therapy 2024-11-29T01:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/a3e26e3ec0241663/major-ai-healthcare-breakthroughs-from-surgical-training-to-clinical-trial-matching 2024-11-29T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d48bba00c202631/counting-blessings-is-key-to-living-with-cancer-cure-today 2024-11-29T00:17:27+00:00 weekly 0.7 https://trial.medpath.com/news/ce019e87e0e6a71e/meta-analysis-confirms-immunotherapy-improves-overall-survival-in-head-and-neck-squamous-cell-carcinoma 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/97370186c1a2608e/iwilfin-eflornithine-approved-by-the-fda-as-the-first-and 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/46a82ae31b7a8f69/resmetirom-shows-promise-in-treating-nash-mash-through-clinical-trials 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/87f4884616d77931/uk-grants-promising-innovative-medicine-status-to-cidp-drug-pharmatimes 2024-11-28T23:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/3f7a259c2ac937d6/follicular-lymphoma-clinical-trial-pipeline-appears-robust-with-50-key-pharma 2024-11-28T23:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/a578ebcb932e08fc/breakthrough-cream-nears-for-skin-cancer-treatment-mirage-news 2024-11-28T23:37:02+00:00 weekly 0.7 https://trial.medpath.com/news/bc4207b5fe086bd6/why-some-people-don-t-lose-weight-with-wegovy-the-conversation 2024-11-28T23:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/3d4922d2c15ec162/urogen-reports-long-term-data-from-study-of-jelmyto-for-lg-utuc-treatment 2024-11-28T22:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/d260cee5c428198b/kras-inhibitor-market-size-share-cagr-of-5-6 2024-11-28T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/ff5f5812d6e28e21/exelixis-updates-from-snda-for-cabozantinib-to-treat-patients-with-previously-treated-pharmabiz 2024-11-28T22:01:38+00:00 weekly 0.7 https://trial.medpath.com/news/5fbe371808217da2/derry-researchers-make-breakthrough-in-early-diagnosis-of-chronic-kidney-disease-and-covid-19 2024-11-28T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/8fd210fabb15936b/expert-explores-the-expanding-applications-of-glp1-therapies-news-medical 2024-11-28T21:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/1d5c8aa8a60c9eb3/landmark-pill-on-a-thread-cancer-screening-trial-welcomes-first-participants 2024-11-28T20:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/1e885cc626f60d03/lot-riding-on-igi-s-promising-trispecific-antibody-for-myeloma-citeline 2024-11-28T19:48:42+00:00 weekly 0.7 https://trial.medpath.com/news/7fb26e4150f00d1d/largest-uk-dairy-co-op-testing-methane-suppressing-drug-on-cattle-herds 2024-11-28T19:43:30+00:00 weekly 0.7 https://trial.medpath.com/news/0f1627bb53de4e05/sellas-announces-positive-data-from-preclinical-studies-indicating-asxl1-mutations-biospace 2024-11-28T18:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/366cf4877f83b604/fda-approved-diabetes-drug-significantly-slows-down-aging-the-brighter-side-of-news 2024-11-28T18:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/a8cec37cf64fabc5/formycon-reports-nine-month-results-for-2024-and-continues-growth-trajectory-with-further 2024-11-28T17:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/8cebea5ce64087e2/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-28T17:35:47+00:00 weekly 0.7 https://trial.medpath.com/news/600cd20a730ce806/france-approves-single-dose-vaccine-johnson-johnson 2024-11-28T17:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/e2a68547cd757d54/cervomed-s-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug 2024-11-28T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/f9f1e570cba54f7c/outlook-holds-out-hope-for-wet-amd-approval-despite-phase-iii-topline-miss-citeline 2024-11-28T17:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/2ccb61ef9befc684/targeting-rett-syndrome-at-the-source-drug-discovery-news 2024-11-28T17:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/5c9614234dedaae3/correcting-and-replacing-altasciences-supports-metsera-in-their-early-stage 2024-11-28T16:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/1725d13e955f6d57/moving-beyond-immunoglobulin-therapy-for-cidp-with-efgartigimod-nature 2024-11-28T16:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/debee912e746bcc5/sequana-medical-s-dsr-2-0-outperforms-traditional-peritoneal-dialysis-solutions-in-study 2024-11-28T16:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/fd5b5ce4172f99df/merryman-discusses-the-role-of-mrd-in-lymphoma-care-and-trials-targeted-oncology 2024-11-28T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/5abf9b164e5d6e5b/very-low-doses-of-rituximab-in-autoimmune-hemolytic-anemia-an-open-label-phase-ii-pilot-trial 2024-11-28T15:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/e20eebaf36bc84d2/sonia-trial-demonstrates-cost-effective-treatment-approach-for-advanced-breast-cancer 2024-11-28T15:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/7f6210ef015e04a5/oral-anticoagulation-in-patients-with-atrial-fibrillation-and-advanced-chronic-kidney-disease 2024-11-28T15:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/70a90dd30b788e7c/six-antisense-oligonucleotide-companies-shaping-the-future-of-genetic-medicine 2024-11-28T14:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/2e2eebd80dee53a1/truqap-emerges-as-new-hope-for-treating-hr-her2-breast-cancer-kbr 2024-11-28T13:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/ae376233f5ff5e47/targeting-il-12-safely-with-intraperitoneal-therapy-represents-key-step-forward-in-ovarian-cancer 2024-11-28T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/6de7b24e24990a8c/new-eu-filings-pink-sheet-key-regulatory-and-policy-insights 2024-11-28T12:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/c25d975aa0840b47/how-to-heal-the-pathology-of-brain-circuitry-with-a-wearable-take-home-device-to-treat-depression 2024-11-28T12:49:12+00:00 weekly 0.7 https://trial.medpath.com/news/885bef875961d7e7/complicated-urinary-tract-infection-uti-clinical-trials-openpr-com 2024-11-28T12:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/33a2f0070c417266/moving-towards-more-personalized-approaches-in-locally-advanced-and-metastatic-colorectal-cancer 2024-11-28T12:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/f4dd457a42ef6733/fasenra-shows-benefit-in-acute-asthma-and-copd-in-phase-ii-trial-yahoo-finance 2024-11-28T12:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/6cc819f1ea75634b/anocca-submits-application-to-ema-for-pancreatic-cancer-trial 2024-11-28T11:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/49f598520b41f043/the-screening-and-anti-raji-lymphoma-effect-of-chiloscyllium-plagiosum-anti-cd20-vnar 2024-11-28T11:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/f40fdbf7778cb455/characterizing-the-pharmacological-interaction-of-the-antimalarial-combination-artefenomel 2024-11-28T11:38:58+00:00 weekly 0.7 https://trial.medpath.com/news/1f55d6e88eb86b81/allocation-and-validation-of-the-second-revision-of-the-international-staging-system-in-the-nature 2024-11-28T11:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/19a5ce8fe3394e62/peter-j-weiden-md-discusses-clozapine-rems-challenges-and-advisory-committees 2024-11-28T10:47:09+00:00 weekly 0.7 https://trial.medpath.com/news/d48263dab3fa60ab/fda-announces-probe-into-bluebird-s-elivaldogene-autotemcel-for-hematologic-malignancies 2024-11-28T10:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/5878559a1af3e42f/monitoring-circulating-tumor-dna-liquid-biopsy-in-stage-iii-braf-mutant-melanoma-patients 2024-11-28T09:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/b372e3098a8c8da5/first-patient-dosed-in-phase-iii-zircon-cp-trial-of-tlx250-cdx-for-kidney-cancer-imaging 2024-11-28T09:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/0e4f0aa0476f6e4e/new-indication-of-olverembatinib-included-into-china-2024-national-reimbursement-drug-list 2024-11-28T09:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/21f6531e48c53ba1/stanford-medicine-study-discovers-what-s-behind-heart-cell-damage-from-chemotherapy 2024-11-28T09:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/84232dd70b4e0969/antengene-announces-xpovio-r-s-new-indication-included-in-2024-china-national 2024-11-28T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/9f5fbf97f367081d/targeted-therapies-show-promise-in-pancreatic-cancer-treatment-but-durability-remains-a-challenge 2024-11-28T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ca78fc0d9565069/celltrion-files-european-ind-for-phase-3-trial-of-darzalex-biosimilar-bio-article-kbr 2024-11-28T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/16e6fca10af43648/novartis-kisqali-r-receives-european-commission-approval-in-a-broad-population-of-patients 2024-11-28T08:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/a327638343ef0b4e/breakthrough-trial-offers-new-hope-for-cystic-fibrosis-patients-drug-target-review 2024-11-28T08:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/30ae442787fc0c52/ivig-treatment-can-lead-to-false-positive-results-in-serum-protein-electrophoresis-testing 2024-11-28T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0bfaf9579647b2bc/trump-s-healthcare-agency-nominations-signal-major-shake-up-in-us-pharma-landscape 2024-11-28T07:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/b0bb40bb297813e7/cutia-therapeutics-unveils-promising-phase-iii-trial-results-markets-insider 2024-11-28T07:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/e461c966cfd7b2cf/astro-issues-new-guidelines-for-radiation-therapy-in-bone-metastases-treatment 2024-11-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fea0a100ba21b9a9/akiram-therapeutics-to-showcase-key-data-on-akir001-at-targeted-radiopharmaceuticals 2024-11-28T06:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/9e001d86dbed230c/galderma-s-phase-iii-olympia-1-trial-results-show-nemolizumab-significantly-improves-prurigo-nodularis-symptoms 2024-11-28T06:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/71350c313b1ce1ef/car-t-cell-therapy-patient-resources-bristol-myers-squibb 2024-11-28T03:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/1ba6c742ed2bdbac/phase-1b-2-study-of-bxq-350-in-metastatic-colorectal-cancer-completes-enrollment 2024-11-28T03:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/9c9bcbdde749a9a0/phase-iii-amd-data-damage-outlook-shares-but-bla-plan-intact-bioworld 2024-11-28T02:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/9e579a51bfb14c7a/lexicon-completes-subject-enrolment-for-dpnp-trial-of-lx9211-clinical-trials-arena 2024-11-28T01:44:45+00:00 weekly 0.7 https://trial.medpath.com/news/264374dfdd5cc21e/pegylated-uricase-well-tolerated-demonstrates-dose-dependent-urate-lowering 2024-11-28T01:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/439b6e85ca5c604f/drug-now-in-testing-has-promise-for-epileptic-seizures-national-union-bulletin-com 2024-11-28T01:22:55+00:00 weekly 0.7 https://trial.medpath.com/news/35ce5f2178152b7e/medscape-extend-launches-revolutionary-hcp-verified-programmatic-advertising-platform-for-pharma-marketers 2024-11-28T01:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/32ac5baf19c4335e/predictive-tool-for-melanoma-could-guide-immunotherapy-choices 2024-11-28T00:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/0f2db34c42e1cce5/eisai-biogen-launch-breakthrough-alzheimer-s-drug-leqembi-in-south-korea-stock-titan 2024-11-28T00:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/64457d0c10650e14/accelerated-access-to-novel-cancer-therapies-at-moores-cancer-center-advamed 2024-11-28T00:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/4908186fe2d0b3b0/igg4-related-disease-clinical-trials-2024-ema-pdma-fda 2024-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8791491cd59cf292/doctors-hail-first-breakthrough-in-asthma-and-copd-treatment-in-50-years-the-guardian 2024-11-27T23:37:03+00:00 weekly 0.7 https://trial.medpath.com/news/d0fb5f722917e012/major-australian-breakthrough-could-revolutionise-hypertension-treatment-news-hub 2024-11-27T22:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/1ff97ddf49e0b9ab/outlook-therapeutics-stock-craters-as-wet-amd-drug-fails-phase-iii-trial 2024-11-27T22:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/b537921579da11f8/myotonic-dystrophy-clinical-trial-pipeline-boom-as-over-20-companies-leading-pr-newswire 2024-11-27T22:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/074594486f04968d/health-canada-approves-novo-nordisk-s-obesity-drug-to-reduce-risk-of-non-fatal-heart-attack 2024-11-27T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/a248935af2059104/fda-rejects-applied-therapeutics-govorestat-for-classic-galactosemia-treatment 2024-11-27T21:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/0156f3b96f1b461e/study-highlights-trimodality-bladder-preserving-therapy-as-possible-option-for-certain 2024-11-27T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/9539e07cb1bfd3e2/polish-scientists-develop-breakthrough-cancer-treatment-english-section-polskie-radio 2024-11-27T20:47:46+00:00 weekly 0.7 https://trial.medpath.com/news/b4c6e3c4fa5f0937/rutgers-cancer-institute-and-rwjbarnabas-health-to-unveil-pioneering-blood-cancer-research 2024-11-27T20:40:07+00:00 weekly 0.7 https://trial.medpath.com/news/b54215b3bf8d9ce8/discussions-swirl-on-the-role-of-pd-1-inhibitors-for-gastric-gej-escc-cancers-with-1 2024-11-27T20:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/3f3dfeb2022f8268/lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2024-11-27T20:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/0e533132401a2129/officials-provide-update-on-phase-3-skyscraper-01-study-docwire-news 2024-11-27T19:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/600078aa41bf9855/winrevair-excels-at-advanced-pah-in-phase-3-trial-all-offered-treatment 2024-11-27T19:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/62886902f25c9441/pbc-therapy-ocaliva-gets-conditional-nod-revoked-in-europe-bioworld 2024-11-27T19:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/ebe260bb399fdca7/nasal-spray-drug-could-revolutionize-alzheimer-s-treatment-the-brighter-side-of-news 2024-11-27T19:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/440eeff0e7bf3208/abequolixron-docetaxel-produces-durable-responses-in-recurrent-advanced-nsclc 2024-11-27T19:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/21ed7d5644ac0d0d/overall-survival-not-improved-with-maintenance-niraparib-in-advanced-ovarian-cancer 2024-11-27T19:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/3b73cc949d3ff03d/hunting-heart-attacks-cardiologist-s-whistleblower-suit-algorithm-predicts-death 2024-11-27T19:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/c8a754b1fda59e8f/scribe-therapeutics-verifies-in-vivo-crispr-based-cardiometabolic-therapies 2024-11-27T18:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/eea1ec8f873e8260/safety-and-efficacy-of-deucravacitinib-in-moderate-to-severe-plaque-psoriasis-for-up-to-3-years 2024-11-27T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/news/6c099e9622d87f96/amgen-s-phase-2-results-were-not-bad-don-t-let-mr-market-fool-you-nasdaq-amgn 2024-11-27T18:19:01+00:00 weekly 0.7 https://trial.medpath.com/news/b590af9f761b5852/healthy-returns-trump-fda-pick-makary-may-be-a-relief-for-biotech-pharma-cnbc 2024-11-27T18:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/13f97f2cb7c9dc9c/widetrial-to-manage-physician-network-for-ibudilast-eap-als-news-today 2024-11-27T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/1783cf1435b8788a/intravenous-lidocaine-for-gut-function-recovery-in-colonic-surgery-a-randomized-clinical-trial 2024-11-27T17:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/1ea74d28ac412152/decoding-sma-progression-hfmse-analysis-spotlights-variability 2024-11-27T17:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/3498422e20686006/tislelizumab-chemo-approved-by-european-commission-for-escc-gej-cancer-network 2024-11-27T17:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/2625b33483044301/car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers-bcm 2024-11-27T16:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/e31c438da177a409/choice-of-end-points-in-heart-failure-trials-cause-specific-or-all-cause-or-both 2024-11-27T16:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/fe83d2b516612c28/bridgebio-s-attr-cm-approval-cassava-s-alzheimer-s-failure-trump-s-cabinet-picks-more 2024-11-27T16:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/f08ce2c2ceede8ac/locoregional-therapies-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis 2024-11-27T16:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/ebfcbe39aad46a4e/toxicity-and-costs-of-cancer-treatment-reduced-by-deferring-cdk4-6-inhibitor-use-nature 2024-11-27T16:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/352949532edd2453/the-race-for-approval-oral-glp-1r-therapies-in-obesity-pharmaceutical-technology 2024-11-27T16:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/dc74585afeb66eff/ptc-therapeutics-als-drug-fails-to-meet-endpoints-as-trials-shut-down-yahoo-finance 2024-11-27T15:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/fcfab9fc22ebc422/rilzabrutinib-first-biosimilar-golimumab-among-new-eu-filings 2024-11-27T15:20:18+00:00 weekly 0.7 https://trial.medpath.com/news/5b399a86b44263bf/lundbeck-initiates-phase-iii-study-medwatch 2024-11-27T15:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/4bb1275203c5a2cc/gravitas-medical-inc-announces-second-fda-clearance-for-its-entarik-system-prweb 2024-11-27T15:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/1e11399044c51067/fda-approves-landiolol-for-treatment-of-supraventricular-tachycardia-pharmacy-times 2024-11-27T14:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/3c82febf2cf45278/the-biggest-pharma-share-moves-of-the-year-so-far-biospace 2024-11-27T14:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/9f98be4173c56499/university-hospital-cologne-and-gustave-roussy-launch-franco-german-research-project 2024-11-27T14:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/643e66f495dca25c/nutriband-secures-hong-kong-patent-for-aversa-abuse-deterrent-fentanyl-patch-technology 2024-11-27T13:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/b360cdf4afc23073/alk-s-pivotal-phase-3-trial-in-children-published-in-reputable-scientific-journal-biospace 2024-11-27T13:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/3aff8f3d3b9fe20b/updated-mdna11-monotherapy-and-combination-clinical-data-from-the-ongoing-phase-1-2 2024-11-27T13:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/91d43055bde38238/aulos-bioscience-doses-first-patient-in-phase-2-cohort-evaluating-the-combination-of-biospace 2024-11-27T13:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/c4a31f85d49113b5/breakthrough-in-early-cancer-screening-go-to-the-dogs-mediapost 2024-11-27T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/ca4872cd0c6d4651/nccn-updates-2024-2025-multiple-myeloma-guidelines-quadruplet-therapy-and-immunotherapy-take-center-stage 2024-11-27T12:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/061c99e68bc537ed/what-you-missed-at-aao-2024-abbv-rgx-314-for-wet-amd-modern-retina 2024-11-27T11:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/e05e190a86848681/outlook-therapeutics-r-announces-preliminary-topline-results-of-norse-eight-clinical-trial 2024-11-27T11:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/20fac3d36660de7d/china-medical-system-gets-green-light-for-obesity-drug-trials-tipranks-com 2024-11-27T11:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/ad5a3afa3913f8df/putting-the-uk-back-on-the-map-for-clinical-trials-nweh-partners-with-cprd 2024-11-27T11:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/c3248f94d372b48d/biostock-elicera-s-ceo-elc-100-stands-apart-from-all-other-standard-treatments 2024-11-27T11:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/676af7b57268ced3/for-agitation-in-alzheimer-disease-a-novel-oral-nmda-receptor-antagonist-could-be-the 2024-11-27T11:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/0d4c4a654df3d9ef/nerve-stimulation-device-might-ease-long-covid-symptoms 2024-11-27T11:11:03+00:00 weekly 0.7 https://trial.medpath.com/news/bdbc46f845725588/beigene-s-tevimbra-wins-eu-approval-after-breakthrough-cancer-survival-data 2024-11-27T11:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/afd99b2cbaf0ad32/although-not-approved-by-the-ema-bavaria-is-considering-buying-the-russian-vaccine 2024-11-27T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/3e8be7109a7c49a4/the-role-of-cabazitaxel-in-patients-with-castration-resistant-and-osseous-metastases-urotoday 2024-11-27T10:35:54+00:00 weekly 0.7 https://trial.medpath.com/news/3612d4c72f44e780/axsome-therapeutics-eyes-approval-after-phase-iii-narcolepsy-win-clinical-trials-arena 2024-11-27T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/526dcbdbf7fb082f/emd-completes-raise-chairman-invests-1m-next-investors 2024-11-27T09:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/f20b29e56bf3a0ab/peptide-cancer-drug-market-research-2024-2030-230-drugs-in-clinical-trials-yahoo-finance 2024-11-27T09:24:23+00:00 weekly 0.7 https://trial.medpath.com/news/911d7271b787bf29/maxilus-study-looks-to-further-elucidate-the-role-of-luspatercept-in-mds-onclive 2024-11-27T09:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/7ddb211e8c2346e1/positive-phase-2-interim-results-from-bexmab-trial-faron-pharmaceuticals-oy 2024-11-27T08:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/236a11461fe2b72f/lundbeck-initiates-a-phase-iii-trial-with-amlenetug-for-the-treatment-of-multiple-system-atrophy 2024-11-27T08:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/4743ef287118b79e/next-biomedical-wins-approval-for-gi-bleeding-prevention-powder-device-ict-article 2024-11-27T08:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/f6497dbda7b0a54c/precision-medicine-in-prostate-cancer-faces-implementation-challenges-despite-progress 2024-11-27T08:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/3532217146ef2a7d/early-stage-trial-finds-stem-cell-therapy-for-retinitis-pigmentosa-is-safe-uc-davis-health 2024-11-27T07:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/d5f8bf0fd5f048c5/real-world-evidence-trials-surge-in-2024-china-leads-global-research-efforts 2024-11-27T07:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/2b76908b1de6307a/gsk-s-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission 2024-11-27T07:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/86aa73b036f4e428/fluoguide-a-s-publishes-interim-report-for-the-period-january-september-2024 2024-11-27T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/ae6ca5e83f60adb8/synact-pharma-receives-eu-trial-approval-for-the-phase-2b-advance-study-with 2024-11-27T06:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/e29159196037e1af/arrowhead-pharmaceuticals-fda-acceptance-of-plozasiran-nda-marks-milestone-in-rnai-therapeutics 2024-11-27T04:22:55+00:00 weekly 0.7 https://trial.medpath.com/news/651f28a5057ec019/first-patient-dosed-in-ridge-1-trial-for-tenaya-s-arv-cardiomyopathy-gene-therapy-tn-401 2024-11-27T04:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/1633a58eb935c4d0/pyc-therapeutics-advances-kidney-disease-drug-trials-markets-insider 2024-11-27T03:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/c2aadb15f9cc288a/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with 2024-11-27T03:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/0f610ae2c1701a0d/phd-student-s-radiopharmaceutical-to-play-key-role-in-clinical-trial-for-lung-cancer-treatment 2024-11-27T03:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/33646f7c4ed0c01a/vectus-biosystems-advances-drug-trials-and-commercialization-tipranks-com 2024-11-27T02:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/b98a4c45e9fd6dc8/newer-epilepsy-medications-used-during-pregnancy-do-not-affect-neurological-development-in-children 2024-11-27T02:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/0c636d520be72b80/news-roundup-oak-street-s-pykosz-departs-cvs-musk-s-neuralink-gains-canadian-clinical 2024-11-27T01:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/3cc05bd5601f9df8/novel-hypofractionated-proton-beam-therapy-for-older-patients-with-newly-diagnosed 2024-11-27T00:55:15+00:00 weekly 0.7 https://trial.medpath.com/news/4650286183490d6f/generative-ai-revolutionizes-drug-safety-monitoring-with-real-time-analysis-capabilities 2024-11-27T00:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/624efafb830644cb/novel-mettl3-inhibitor-elicits-clinical-activity-across-tumor-types-targeted-oncology 2024-11-27T00:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/b3f4560509c34ddd/viromed-medical-ag-advances-cold-plasma-technology-as-digital-antibiotic-for-ventilator-associated-pneumonia-prevention 2024-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/274316761b4de628/amgen-s-phase-ii-maritide-data-lack-clarity-market-hoped-for-citeline 2024-11-26T23:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/f458a405deeeed1a/an-rna-biotech-draws-the-blueprint-for-a-late-stage-dravet-syndrome-trial-and-beyond 2024-11-26T23:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/e4a4fb840eb408f7/tc-s-lori-quinn-tapped-for-huntington-s-disease-study-supported-by-the-fda 2024-11-26T22:35:06+00:00 weekly 0.7 https://trial.medpath.com/news/9e8f80cfe68baa2a/healthcare-september-and-october-2024-regulatory-updates 2024-11-26T21:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/6d7991ba5e7431a5/alzheimer-s-trials-fail-blood-test-predicts-tau-neuroscience-moves-to-bluesky 2024-11-26T20:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/73b6724d5902ed3e/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-11-26T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/cd7a67a70b2efef3/multiomics-approaches-disclose-very-early-molecular-and-cellular-switches-during-insect-nature 2024-11-26T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/67e6c0d3b59c8cba/asgct-s-q3-2024-landscape-report-cgtlive-r 2024-11-26T18:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/d1e321e71ef6f19b/people-with-hiv-can-now-receive-livers-kidneys-from-hiv-positive-donors 2024-11-26T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/a6b37ac39e052ab4/failure-of-astrazeneca-s-azd4041-a-blow-for-non-opioid-oud-treatments 2024-11-26T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/2171ae23f37895fc/assessing-omaveloxolone-s-positive-long-term-safety-profile-david-lynch-md-phd 2024-11-26T17:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/ffed695b9615360b/spatially-organized-tumor-stroma-boundary-determines-the-efficacy-of-immunotherapy-in 2024-11-26T17:33:21+00:00 weekly 0.7 https://trial.medpath.com/news/9d38b33bd81a9dba/an-early-switch-in-first-line-therapy-improves-outcomes-of-advanced-stage-g-gejc-nature 2024-11-26T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/61af884351024260/tamoxifen-response-rate-influenced-by-gut-microbiome-inside-precision-medicine 2024-11-26T16:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/b444632a0a4419b7/hit-and-miss-for-cdk4-6-inhibitor-in-recurrent-brain-cancer-medpage-today 2024-11-26T16:51:38+00:00 weekly 0.7 https://trial.medpath.com/news/ec9dad99dcf1d631/geographic-disparities-in-gynecologic-oncology-clinical-trial-availability-in-the-us-jama-network 2024-11-26T16:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/ced84ce2f6697099/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-r-to-the-u-s-fda 2024-11-26T16:45:12+00:00 weekly 0.7 https://trial.medpath.com/news/a3d9f088a74ad73c/bagegni-receives-national-cancer-institute-award-washu-medicine 2024-11-26T16:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/9e90eaf9cb11fa30/safilens-receives-fda-approval-optician-online 2024-11-26T16:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/84feed4073e51de8/nexus-pharmaceuticals-receives-fda-approval-for-methylene-blue-injection-usp 2024-11-26T16:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/36638a590baa2265/gene-signature-identified-for-high-risk-form-acute-lymphoblastic-leukemia 2024-11-26T15:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7dbb9dd86ae6ad8/trials-and-tribulations-of-cell-therapy-for-heart-failure-an-update-on-ongoing-trials-news 2024-11-26T15:48:33+00:00 weekly 0.7 https://trial.medpath.com/news/5864e286a20d9d5f/crispr-clinical-trial-targets-sickle-cell-at-its-genetic-roots-synbiobeta 2024-11-26T15:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/3a0912c637a99e3c/pop-bio-awarded-2-84m-phase-ii-sbir-for-seasonal-influenza-vaccine-development 2024-11-26T15:43:04+00:00 weekly 0.7 https://trial.medpath.com/news/77eaa1b7d00fd97a/your-skin-color-may-affect-how-well-a-medication-works-for-you-but-the-research-is-way-behind 2024-11-26T15:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/36b0ade460819a84/onvansertib-combo-shows-significant-efficacy-in-kras-colorectal-cancer 2024-11-26T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/9f142f87bade4afe/initial-impressions-of-the-cepheus-clinical-trial-in-transplant-not-preferred-ndmm 2024-11-26T14:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/ff497548f9f75ffe/vir-biotechnology-to-host-virtual-investor-event-on-pro-xtentm-masked-t-cell-engager-programs 2024-11-26T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/825e958be564a598/soleno-s-pws-drug-dccr-gets-3-month-fda-review-extension-no-safety-concerns-cited 2024-11-26T13:39:49+00:00 weekly 0.7 https://trial.medpath.com/news/9cb4765d1535316b/dmd-gene-therapy-gnt0004-set-to-enter-phase-3-trial-in-europe-us 2024-11-26T13:25:56+00:00 weekly 0.7 https://trial.medpath.com/news/ebb4e32a13808eab/ensysce-biosciences-launches-key-trial-for-breakthrough-opioid-drug-backed-by-14m-nida-grant 2024-11-26T13:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/7ef5237f4c891e43/scholar-rock-s-stock-target-increased-following-sma-study-results 2024-11-26T13:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/d955c6afd10e0f09/maat-pharma-eyes-phase-ii-after-early-success-in-als-microbiome-trial-yahoo-finance 2024-11-26T13:06:54+00:00 weekly 0.7 https://trial.medpath.com/news/6c11942cec6ad43f/otsuka-submits-new-drug-application-in-japan-for-bempedoic-globenewswire 2024-11-26T13:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/f5573ecc16904f71/medigene-ag-announces-refocus-of-corporate-strategy-and-organizational-realignment 2024-11-26T13:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/6e34495f15633257/briacell-s-breast-cancer-therapy-shows-13-4-month-survival-rate-in-phase-2-trial 2024-11-26T12:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/d0eff2c0c572ba87/study-unlocks-the-secrets-of-beta-cell-regeneration-news-medical 2024-11-26T12:56:29+00:00 weekly 0.7 https://trial.medpath.com/news/94ef2c4bb3cc341a/severe-toxicities-in-amazonian-populations-and-the-role-of-precision-medicine-in-acute-nature 2024-11-26T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/de994b8d642bfc80/alector-s-abbvie-partnered-alzheimer-s-program-fails-phase-ii-triggering-a-17-layoff 2024-11-26T12:30:28+00:00 weekly 0.7 https://trial.medpath.com/news/b5faed220168bf0a/brenig-therapeutics-announces-the-initiation-of-first-in-human-clinical-trial-of-bt-267-a 2024-11-26T12:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/daf8e1944c859c89/arrowhead-pharma-lands-825m-mega-deal-with-sarepta-up-to-10b-in-milestones-stock-titan 2024-11-26T12:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/78d9beedd5a5aaa6/crohn-s-disease-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-26T12:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/ce64e674822f7142/amgen-to-host-webcast-to-discuss-maritide-phase-2-results-and 2024-11-26T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/3901d2c95422694f/mvitro-s-needle-free-blood-sampling-device-ortiv-wins-fda-approval-kbr 2024-11-26T11:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/cd0f4c58f1cfafa2/greenwich-lifesciences-partners-with-gim-in-italy-stock-titan 2024-11-26T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/4a18e55f38f3cc08/an-assortment-of-journal-abstracts-to-enhance-oncology-care 2024-11-26T11:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/ccea707b1e29e3b2/ziftomenib-shows-promise-in-treatment-resistant-aml-oncology-times 2024-11-26T11:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/8ee33d74ef1d76ea/delta-fly-pharma-inc-progress-update-of-the-phase-iii-clinical-trial-of-dfp-14323-news 2024-11-26T11:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/173f3374c01f56a7/study-examines-efficiency-of-physiotherapy-in-treating-preventing-uncomplicated-acquired-myopia 2024-11-26T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/d445d0c735eacf64/there-s-a-best-option-for-patients-with-head-and-neck-cancer-who-can-t-take-cisplatin 2024-11-26T11:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/7b08a081b8ec68a9/application-of-machine-learning-algorithms-to-identify-serological-predictors-of-covid-19 2024-11-26T10:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/f37e414bc88d20c3/olema-oncology-to-present-new-data-combining-palazestrant-globenewswire 2024-11-26T10:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/f54baf21f5878850/imcheck-to-present-encouraging-interim-results-in-aml-globenewswire 2024-11-26T10:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/56b4828f5d7cb9a2/shilpa-medicare-gets-nod-to-conduct-phase-iii-clinical-trials-for-recombinant-human-albumin-20 2024-11-26T08:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/9aa746fd36f15e5f/celldex-therapeutics-swot-analysis-barzolvolimab-stock-shows-promise-in-urticaria-treatment 2024-11-26T08:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/ea55a7f014f06d87/consuming-chinese-medicinal-tea-eases-sjogren-s-symptom-severity 2024-11-26T08:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/e815924132ffa178/anocca-announces-submission-of-clinical-trial-application-for-multi-asset-trial-vidar-1-in 2024-11-26T08:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/d43e05254a83f0e9/hemogenyx-pharmaceuticals-explains-share-consolidation-greenlight-for-clinical-trial 2024-11-26T07:33:26+00:00 weekly 0.7 https://trial.medpath.com/news/3033b2da5c0c06a7/roche-reports-update-on-phase-iii-skyscraper-01-study-results-globenewswire 2024-11-26T06:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/bef388c7416bf3c7/va-expands-cancer-care-access-through-innovative-programs-and-telehealth-services 2024-11-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5776e879f7d9e3a3/gc-biopharma-and-novel-pharma-first-patient-dosed-in-global-phase-i-clinical-trial-for 2024-11-26T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/90444549393b60fd/emerging-data-on-oral-serds-targeted-oncology 2024-11-26T05:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/37a46fa9a85999b2/slope-and-labconnect-launch-revolutionary-api-integration-to-transform-clinical-trial-sample-management 2024-11-26T04:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/188cc6268a46cdbf/eu-postpones-decision-on-biontech-and-pfizer-vaccine-approval-telegrafi 2024-11-26T03:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/0330daf554505343/deep-brain-stimulation-of-hippocampus-in-treatment-resistant-schizophrenia-dbs-hits 2024-11-26T02:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/5de17bb296d3601b/long-term-data-solidify-the-role-of-zanubrutinib-in-r-r-cll-with-alexey-danilov-md-phd 2024-11-26T01:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/a123e5f9c90e487a/pmcpa-sanctions-moderna-for-code-violations-in-covid-19-vaccine-promotion-and-trial-recruitment 2024-11-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f900b82e00b8c2e/clinical-outcome-assessments-and-biomarkers-in-charcot-marie-tooth-disease-pubmed 2024-11-25T23:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/d58ddb5cea736a11/alector-therapeutics-novel-alzheimer-s-strategy-fails-in-phase-2-trial-stat-news 2024-11-25T22:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/0e1100ddc2935325/empyrean-therapeutics-acquires-tlr-2-antagonist-molecule-from-eos-therapies-to 2024-11-25T22:39:27+00:00 weekly 0.7 https://trial.medpath.com/news/660dd42cadd22aba/many-people-remain-excluded-from-glp-1-clinical-trials-for-weight-loss-healio 2024-11-25T22:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/580b61d4004c6a26/zimmer-biomet-receives-fda-approval-for-oxford-r-cementless-partial-knee-only-pr-newswire 2024-11-25T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/9457576a6fbc49f5/emerald-subgroup-analysis-elacestrant-in-endocrine-sensitive-disease-targeted-oncology 2024-11-25T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/8fdfbad0ba75c7b9/a-universal-gene-therapy-for-diamond-blackfan-anemia-is-poised-for-clinical-trials 2024-11-25T21:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/f46923c00344666c/efficacy-and-safety-of-human-umbilical-cord-derived-mesenchymal-stem-cells-versus 2024-11-25T20:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/ab56c1d3865b5cb3/xenon-pharmaceuticals-swot-analysis-stock-poised-for-breakthrough-in-epilepsy 2024-11-25T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/78305d49b5e87e91/modified-folfoxiri-plus-cetuximab-versus-bevacizumab-in-ras-wild-type-metastatic-nature 2024-11-25T17:58:23+00:00 weekly 0.7 https://trial.medpath.com/news/7ff8c5e1d16c3c71/mereo-biopharma-s-swot-analysis-rare-disease-stock-poised-for-growth-investing-com 2024-11-25T17:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/4300a56eaf4b067c/biohaven-shares-retain-outperform-rating-as-baird-highlights-optimism-for-obesity-phase-2-trial 2024-11-25T17:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/812228bf9a1c74ac/blue-lake-and-cyanvac-report-positive-phase-2a-data-for-intranasal-covid-19-vaccine-candidate 2024-11-25T17:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/a0c1eccde7a48291/briohealth-solutions-begins-patient-enrollment-in-innovate-trial-of-briovad-r-system-for 2024-11-25T17:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/ce5de60f9371a5b9/rti-surgical-announces-first-patient-enrolled-in-investigational-device-exemption-ide-for 2024-11-25T17:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/6cb1d7160ff48ab6/msk-care-for-a-young-woman-living-with-stage-4-egfr-lung-cancer 2024-11-25T17:27:56+00:00 weekly 0.7 https://trial.medpath.com/news/eb07a11ee558bb26/updated-phase-iii-mirasol-trial-results-mirvetuximab-soravtansine-vs-chemotherapy-in 2024-11-25T17:14:11+00:00 weekly 0.7 https://trial.medpath.com/news/d1e9a25ccd1ad71c/early-promise-for-pi3k-inhibitor-in-brain-metastases-medpage-today 2024-11-25T17:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/8c73eae30e2604b6/patient-reported-quality-of-life-and-adherence-outcomes-after-integrating-exclusive-liquid 2024-11-25T17:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/d70bb751351399d4/sel-212-advances-refractory-gout-outcomes-with-prolonged-treatment-hcplive 2024-11-25T17:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/4e057d4d2d1fbecc/new-data-could-help-merck-expand-use-of-cardiovascular-drug-biopharma-dive 2024-11-25T17:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/8bc3caf4557f4580/outcomes-in-randomized-clinical-trials-testing-changes-in-daily-water-intake 2024-11-25T16:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/236302144bd84909/biotech-breakthrough-a-new-hope-for-cancer-treatment-shocking-ipo-plans-revealed 2024-11-25T16:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/0de7b08fa7cec959/igc-pharma-announces-additional-phase-2-interim-results-highlighting-cognitive-benefits 2024-11-25T16:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/921d2cfbb32bc4a6/fda-advised-to-update-labels-on-glp-1-weight-loss-drugs 2024-11-25T16:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/c78e75b4f4d6f01f/biohaven-drug-misses-in-phase-iii-for-sma-will-be-tested-in-obesity-biospace 2024-11-25T15:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/f1d45f97b7cf4bf3/advances-in-small-cell-lung-cancer-classification 2024-11-25T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/0f4ae562201ef3e5/incyte-to-spotlight-new-data-including-a-late-breaking-oral-presentation-for-tafasitamab-in 2024-11-25T15:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/51726df5121b6ced/managinglife-launches-innovative-psychology-intervention-for-post-surgical-pain-and-opioid-use 2024-11-25T15:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/2705497625fbaac4/ec-ordered-to-pay-cost-of-pharmamar-vs-ema-case-european-biotechnology-magazine 2024-11-25T15:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/abf1f1eb6e61ac5b/bridgebio-shares-retain-buy-rating-as-h-c-wainwright-highlights-attruby-fda-approval 2024-11-25T14:57:55+00:00 weekly 0.7 https://trial.medpath.com/news/7e9973b167e2abc6/cassava-sciences-controversial-alzheimer-s-drug-fails-to-hit-primary-goal-in-pivotal-study 2024-11-25T14:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/9f4b57b5dba348a7/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-hep 2024-11-25T14:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/3e4160caa0e95105/weekly-report-phase-3-data-for-jnj2113-expert-discussions-and-more 2024-11-25T14:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/4dde9bb631762962/readout-newsletter-trump-s-cdc-fda-nominees-merck-alnylam-stat-news 2024-11-25T14:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/501494dbf6524e9c/bioadaptives-inc-announces-institutional-review-board-approval-of-a-human-clinical-trial 2024-11-25T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/ed8c89e606042dce/bioadaptives-launches-clinical-trial-for-weight-management-alternative-to-glp-1-drugs 2024-11-25T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/d67f04658ace097a/cassava-stock-plunges-as-alzheimer-s-drug-fails-late-stage-study-investopedia 2024-11-25T14:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/351cd3a68b5dee6f/food-allergy-longbio-s-lp-003-achieves-its-fourth-ind-approval-morningstar 2024-11-25T14:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/920dff8673941f2d/bioadaptives-inc-announces-institutional-review-board 2024-11-25T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/b2a710e65b1172ed/neurotech-innovator-uneeg-medical-receives-fda-breakthrough-device-designation 2024-11-25T14:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/12d2221e1a4e479b/new-malaria-vaccine-shows-high-protection-in-clinical-trial-medical-xpress 2024-11-25T14:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/e523b8974f17763a/cns-pharma-s-berubicin-shows-higher-patient-retention-in-pivotal-gbm-trial-cnsp-stock-news 2024-11-25T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/731a5a9ab0444164/fda-study-adds-to-concerns-that-asthma-drug-can-harm-mental-health 2024-11-25T13:57:20+00:00 weekly 0.7 https://trial.medpath.com/news/5f14459135086b99/mjff-awards-grant-to-study-skin-test-that-detects-alpha-synuclein-in-parkinson-s 2024-11-25T13:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/03ff87ec983f7c07/brain-shrinkage-in-alzheimer-s-drugs-shows-effectiveness-mirage-news 2024-11-25T13:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/5cc27b5af08b96d7/seven-top-pharma-companies-adopt-phasev-s-machine-learning-technology-for-drug 2024-11-25T13:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/9979885a8b803d7b/south-korean-researchers-develop-clinical-laboratory-test-that-diagnoses-sepsis-faster 2024-11-25T13:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/b904ab7c28e528e2/dr-schiff-on-pfs-and-os-data-with-temozolomide-plus-radiation-in-grade-ii-glioma 2024-11-25T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/8a4993dda9c8c114/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T13:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/fe240b8c04ae6f0a/bridgebio-gets-fda-nod-for-attruby-to-treat-attr-cm-patients 2024-11-25T13:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/d1747da48430c50b/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/3f0e4e17eadf60bf/nrx-pharmaceuticals-nasdaq-nrxp-announces-publication-of-paper-entitled-quality 2024-11-25T13:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/1c5fe7812583d408/citius-pharma-progresses-with-fda-on-mino-lok-approval-investing-com 2024-11-25T13:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/e93f5a2cfe234bc1/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug-yahoo-finance 2024-11-25T13:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/7e2eb907b2819db6/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/c087d1f1d1e34887/citius-pharma-advances-mino-lok-after-successful-fda-meeting-phase-3-trial-results 2024-11-25T13:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/77ee3f259d0f6176/nrx-pharma-achieves-94-5-rating-accuracy-breakthrough-in-depression-trial-method 2024-11-25T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/53cbb20b48d24070/long-covid-patients-push-to-see-federal-research-refocused-on-treatments-npr 2024-11-25T13:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/e767e8d698b57e0a/fda-grants-orphan-drug-status-to-rag-21-for-treating-fus-als-als-news-today 2024-11-25T13:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/63af3d48242fc694/tislelizumab-pushes-hcc-field-forward-with-2024-nccn-guideline-category-1-recommendation 2024-11-25T13:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/2dd88281349b0454/bridgebio-s-attruby-to-treat-heart-condition-attr-cm-receives-fda-approval 2024-11-25T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/6ebc456193896796/breakthroughs-and-setbacks-in-the-pharmaceutical-industry-health-devdiscourse 2024-11-25T13:01:34+00:00 weekly 0.7 https://trial.medpath.com/news/fd31de4b2b9429aa/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/06a7daaa6aa5519b/world-s-1st-ai-made-lung-disease-drug-gets-phase-2-trial-in-us-china 2024-11-25T12:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/2700837654913ccd/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine 2024-11-25T12:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/9e7cf19708d8ff92/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints-stock-titan 2024-11-25T12:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/01ca817dbac9b5a4/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-markets-data 2024-11-25T12:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/c5b734a24d968846/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints 2024-11-25T12:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/78055bc63771dce7/anavex-s-alzheimer-s-drug-trial-results-accepted-for-peer-review-publication-avxl-stock-news 2024-11-25T12:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/8e3ac41f4a043c77/j-j-and-protagonist-share-promising-phase-3-results-for-icotrokinra-in-plaque-psoriasis 2024-11-25T12:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/b22d93f9a989e962/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/8405387017602f9a/fda-approves-bridgebio-s-attruby-to-treat-rare-heart-disease-attr-cm-pmlive 2024-11-25T12:23:54+00:00 weekly 0.7 https://trial.medpath.com/news/e9d5ebba55fbd104/msd-s-welireg-approved-by-nmpa-to-treat-vhl-disease-associated-tumours-yahoo 2024-11-25T12:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/9e2b3f79c2dcd0ff/orbus-s-combo-misses-primary-endpoint-in-phase-iii-brain-cancer-trial 2024-11-25T12:20:02+00:00 weekly 0.7 https://trial.medpath.com/news/06c5ff84f7a90931/edwards-lifesciences-announces-positive-results-in-one-year-tavi-trial 2024-11-25T12:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/a7b7ce8b4dd74545/truqap-r-capivasertib-combination-in-pten-deficient-metastatic-hormone-astrazeneca-us 2024-11-25T12:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/40a9672e96532539/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T12:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/506595cac8f42d47/exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-25T12:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/dd3cf4b18156fc3e/clearside-biomedical-showcases-breakthrough-scs-technology-after-10000-successful-injections 2024-11-25T12:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/f3303b8b964cafc2/lifesignals-receives-fda-510-k-approval-for-ubiqvuetm-2a-multiparameter-system 2024-11-25T12:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/8b63f222b26bd023/fda-approves-stemcyte-s-cord-blood-stem-cell-therapy-bla 2024-11-25T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/e30db64ab8d73cf5/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-pr-newswire 2024-11-25T12:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/596f0f242c538f36/alnylam-s-vutrisiran-fda-review-set-for-attr-cm-treatment-expansion-alny-stock-news 2024-11-25T12:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/5921b1abf5ed1830/truqap-trial-shows-breakthrough-in-pten-deficient-prostate-cancer-treatment-azn-stock-news 2024-11-25T12:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/6bcdd88d4099fd42/alnylam-announces-u-s-food-and-drug-administration-acceptance-of-supplemental-new 2024-11-25T12:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/077fb328f55cdf79/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-morningstar 2024-11-25T12:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/855467cc6311d61c/kanglin-biotechnology-announces-20-million-series-a-globenewswire 2024-11-25T12:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/d0103cca75fc1204/china-s-nmpa-approves-msd-s-welireg-for-vhl-treatment-pharmaceutical-technology 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/319b1d23dcf683f4/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/674fe74e391683d6/clearside-biomedical-extends-global-footprint-with-numerous-globenewswire 2024-11-25T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/1f929bf4a35cf080/fda-grants-510-k-clearance-to-philips-rocc-capabilities-yahoo-finance 2024-11-25T12:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/7da8a99204057111/merck-s-winrevair-shows-promise-in-pah-phase-3-trial-investing-com 2024-11-25T12:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/aaad31468fd97478/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/63350c524fe30a09/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/d02b90c09bb18315/advantage-therapeutics-launches-klothea-bio-to-develop-klotho-based-anti-aging-therapies 2024-11-25T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/995174cc0b5223d7/merck-s-winrevair-shows-breakthrough-results-in-phase-3-pah-trial-study-halted-early 2024-11-25T11:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/52d4ac855dfd5fe6/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspension 2024-11-25T11:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/90edb152d01670dd/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/d698ab4f74a66213/study-points-to-a-strategy-for-inhibiting-hyper-progression-of-melanoma-news-medical 2024-11-25T11:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/c9c9b6bdf4ed3780/clinical-efficacy-and-safety-of-the-superpulse-thulium-fiber-laser-and-holmium-laser-for-trials 2024-11-25T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/d1bc6b0d3e9ce275/study-finds-bone-density-loss-associated-with-levothyroxine-news-medical 2024-11-25T11:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/89a2e448e63ea25e/scg-s-hbv-t-cell-therapy-shows-promise-in-phase-i-trial 2024-11-25T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/b1edff8e7db6de1c/us-fda-grants-approval-for-zanidatamab-ziihera-bispecific-antibody-for-biliary-tract-cancer 2024-11-25T11:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/42c70cbe3806ef89/an-open-label-phase-iii-study-to-assess-the-efficacy-and-safety-of-cy-opth 2024-11-25T10:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/7caf8e333c197ba5/the-cost-effectiveness-of-peer-education-on-medication-adherence-in-the-elderly-with-hypertension 2024-11-25T10:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/15b6445c6874ba4e/ticaros-unveils-breakthrough-switchable-car-t-therapy-for-solid-cancers-kbr 2024-11-25T10:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/273cbbfa8c9f2060/intravenous-administration-of-blood-brain-barrier-crossing-conjugates-facilitate-nature 2024-11-25T10:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/4522fcae66c30839/homegrown-preoperative-lung-cancer-drug-leclaza-lowers-cancer-stages-in-55-of-patients 2024-11-25T10:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/dfb50d536076f536/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:37:15+00:00 weekly 0.7 https://trial.medpath.com/news/b6be45a0c5090bda/europe-is-losing-competitiveness-in-the-medical-field-regulatory-regime-to-blame 2024-11-25T10:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/6e186ced3c6f79d9/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and 2024-11-25T10:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/47ef1beb5ec86ebf/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/54a0e41fea12c9b5/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-pharmaceutical-technology 2024-11-25T10:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/7493f4119366d283/pharmacodynamics-of-the-s1p1-receptor-modulator-cenerimod-in-a-phase-2b-randomised 2024-11-25T09:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/eeedf8b45350b7a1/using-an-electronic-tool-to-screen-patients-eligibility-for-clinical-trials-nursing-times 2024-11-25T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/ac69057f366ec71f/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-yahoo 2024-11-25T09:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/7c5d5e71c327eb3c/gsk-s-blenrep-combinations-accepted-for-review-by-us-fda-morningstar 2024-11-25T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/ff51ca015d0fdaf0/care-bundles-to-improve-enteral-nutrition-management-in-stroke-patients-trials-biomed-central 2024-11-25T09:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/2a5b5e7a3cb737f6/gsk-fda-accepts-blenrep-combination-for-review-in-treatment-of-relapsed-refractory 2024-11-25T09:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/e637a237f1adcfe4/injecting-oxygen-microbubbles-boston-children-s-answers 2024-11-25T09:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/df3490a2b72d79f8/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/9980ffa68459ceb1/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/d95a82a0e2bd6199/bridgebio-poised-to-challenge-pfizer-after-attruby-approval-pharmaphorum 2024-11-25T08:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/921c056d38d9f04b/efficacy-and-safety-of-the-combination-of-decitabine-and-chag-priming-regimen-in-the-nature 2024-11-25T08:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/32c2e74dea9c737e/astrazeneca-prostate-cancer-drug-shows-promising-phase-iii-results-lse-azn 2024-11-25T08:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/9a7189ef090ed649/roche-gets-fda-approval-for-first-companion-diagnostic-for-her2-treatment-in-biliary 2024-11-25T08:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/48e2e58375dfcb33/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T07:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/39e0607eb9f4311c/intracoronary-administration-of-tenecteplase-to-prevent-pci-related-myocardial-infarction-in-trials 2024-11-25T07:34:57+00:00 weekly 0.7 https://trial.medpath.com/news/2f2379362e23c659/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T07:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ee304c88e886f5b9/usfda-accepts-blenrep-combinations-for-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-25T07:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/26b168cd80978875/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-gsk 2024-11-25T07:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/36d84daa36bab661/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-astrazeneca 2024-11-25T07:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/48e4c4b79f92eb2a/vir-biotechnology-ceo-to-present-at-major-healthcare-conferences-in-early-2024 2024-11-25T07:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/e0e3ac27cce9cd3c/nasal-polyposis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/ee60405f50a3fe08/mydriasis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/fdf6f19a73df4ffc/rising-lung-cancer-rates-among-young-adults-prompt-shift-to-precision-oncology-approaches 2024-11-25T06:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/9327f270aa837637/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/c08d48b751c97748/combination-of-eflornithine-and-lomustine-demonstrates-clinically-meaningful-biospace 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/ed436251af76752d/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/7b1ae1dee17bcca9/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T06:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/96fcbd77e9f5ed56/roche-secures-fda-approval-for-first-ever-her2-test-in-biliary-tract-cancer-stock-titan 2024-11-25T06:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/88d0016db6c9abdc/novartis-highlights-new-96-week-results-from-phase-iii-globenewswire 2024-11-25T06:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/4ed3263ddbd0dc73/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/6fdcf351b869c7a9/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/e3647c346de8cfe8/answer-als-cedars-sinai-collaboration-single-cell-protein-profiling-chapsvision 2024-11-25T06:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/3d704f15ded4979c/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-biospace 2024-11-25T06:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/5ba7a80645e477a6/alkannin-induces-g2-m-phase-arrest-apoptosis-and-inhibition-of-invas-dddt 2024-11-25T05:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/cb8a1a7e3c660fed/johnson-johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya 2024-11-25T05:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/3c3662b8c02e50e9/acne-vaccine-clinical-trials-to-be-held-here-by-a-star-national-skin-centre-and-sanofi 2024-11-25T05:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/9c7145d0c7e541fc/mursla-bio-announces-promising-results-for-evoliver-test-in-liver-cancer-detection 2024-11-25T05:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/effe24e80b2cc1fa/cassava-sciences-to-hold-corporate-update-on-november-25th-gurufocus 2024-11-25T05:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/9861d5c0aa80ab97/fda-action-alert-applied-therapeutics-awaits-verdict-on-rare-disease-therapy-biospace 2024-11-25T05:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/e66646882fac36a9/embattled-sage-dealt-deeper-blow-with-huntington-s-failure-biospace 2024-11-25T05:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/3086509f37961cf3/bridgebio-s-breakthrough-in-rare-heart-condition-treatment-health-devdiscourse 2024-11-25T05:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/1ef72b28f3412f2c/game-changing-solution-for-heart-inflammation-david-elsley-cardiol-therapeutics 2024-11-25T04:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/c6cdf1e5bf5b6d2f/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-25T04:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/e192cc2c05333f79/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine-pnubiovax-pharmabiz 2024-11-25T04:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/b397fc531c84cc76/quick-listen-scrip-s-five-must-know-things-citeline-news-insights 2024-11-25T04:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/673946509c3f3712/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T03:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/9b45f6e3a6dcd66b/fda-links-asthma-drug-singulair-to-mental-health-side-effects-suicides-times-now 2024-11-25T02:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/78862ca5bdc86e49/european-drug-shortages-hit-record-levels-norway-and-generics-most-affected 2024-11-25T02:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/4686fa795fea20d0/break-it-down-neurotech-s-human-adult-study-tick-of-approval-for-cannabinoid-drug 2024-11-25T02:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/c60c41a3315e8ef4/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/255441f3d722bd9e/how-stimulating-a-nerve-could-stop-uncontrolled-bleeding-in-postpartum-women-kmvt 2024-11-25T01:28:09+00:00 weekly 0.7 https://trial.medpath.com/news/38b11e428257f660/effective-sponsor-oversight-critical-for-cro-partnerships-in-clinical-trials-industry-leaders-emphasize 2024-11-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/eb6f36eaf9cf695f/cassava-sciences-to-hold-corporate-update-on-november-25th-quantisnow 2024-11-25T01:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/43faca72e59c73a8/neurotech-international-advances-nti164-drug-trials-markets-insider 2024-11-25T01:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/18a268c47c514fdd/cassava-sciences-to-hold-corporate-update-on-november-25th-globenewswire 2024-11-25T01:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/948399e2d07b2995/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024-pr-newswire 2024-11-25T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/a281903a80f7d9c1/jacobio-pharmaceuticals-advances-with-new-cancer-drug-trial-tipranks-com 2024-11-25T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/3f828cd38ed1f2fe/spatial-interactions-of-immune-cells-as-potential-predictors-to-efficacy-of-toripalimab-plus 2024-11-25T00:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/f61f28e74ec649d9/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024 2024-11-25T00:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/abb24e80b90f0e1a/jefferies-reaffirms-buy-rating-on-argenx-stock-ups-target-amid-promising-trial-updates 2024-11-25T00:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/b86b6ae128c2bc5d/ssy-group-gains-approval-for-key-drug-development-tipranks-com 2024-11-25T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/b320ca39fa8e83fc/unveiling-the-progress-and-challenges-in-the-fight-against-hiv-technology-networks 2024-11-25T00:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/264b97adadb2a507/fda-approves-rystiggo-r-rozanolixizumab-noli-for-generalized-myasthenia-gravis-treatment 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63a4b8563442ef36/real-world-safety-analysis-reveals-new-adverse-events-for-plecanatide-beyond-clinical-trial-data 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f78b9930ba257ec2/alpheus-medical-announces-positive-phase-1-2-trial-results-for-the-treatment-of-recurrent-high-grade-gliomas 2024-11-24T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/8855c2891c20ac45/miracle-drug-sees-blood-cancer-patients-given-second-chance-of-life-uk-daily-express 2024-11-24T22:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/b9a8830ea93969e9/neurotech-international-advances-nti164-drug-trials-tipranks-com 2024-11-24T21:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/ccb0ff44c01492ee/comparison-of-two-doses-of-vitamin-d3-in-critically-ill-patients-undergoing-continuous-renal 2024-11-24T20:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/8ef245c136c60119/these-2-key-milestones-awaiting-recce-pharmaceuticals-could-be-very-exciting-and-value-accretive 2024-11-24T20:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/3ae728285aad4e05/idh-inhibitor-activity-in-brain-cancer-persists-with-longer-follow-up-medpage-today 2024-11-24T20:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/f84ea352677f22f6/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T19:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/f6a522914f874bcf/european-medicines-agency-ema-grants-orphan-medicinal-product-designation-for-ocu410st 2024-11-24T19:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/80291d06c10d2bb7/accelerated-approval-sought-for-rp1-nivolumab-combo-for-pretreated-melanoma 2024-11-24T19:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/2b261a0ad26d258b/fda-highlights-and-health-concerns-from-heart-drugs-to-mpox-updates-devdiscourse 2024-11-24T18:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/6f299fc082a38d1e/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/b6cba23769bf4a6f/enveda-130-million-series-c-raised-to-translate-nature-into-new-medicines 2024-11-24T18:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/3170b3360963ec12/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/news/4be2be499d44d2f7/membrane-becomes-latest-rct-to-demonstrate-mma-embolisation-s-benefits-in-csdh-treatment 2024-11-24T18:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/d7a315b5edd2a35e/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/dd07eb65671d379b/larotrectinib-induces-rapid-durable-responses-in-pediatric-patients-with-trk-fusion 2024-11-24T18:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/1994473abea07101/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T17:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/2dc12be9901c2f13/conduct-phase-iii-ct-cdsco-panel-tells-zydus-healthcare-on-glycopyrrolatem-plus 2024-11-24T17:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/6387afd3d3507aba/real-world-results-of-durvalumab-tremelimumab-in-u-hcc-show-promise-despite-line-of-therapy 2024-11-24T16:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/ea672c6ec4fe5b33/researchers-id-key-mechanism-behind-drug-resistant-prostate-cancer-fingerlakes1-com 2024-11-24T15:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/b3fa8c859bf8f4c2/zymeworks-gains-buy-rating-amid-fda-approval-and-market-expansion-potential-for-zanidatamab 2024-11-24T15:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/7b458ecc8c415054/founded-in-1954-korea-has-chosen-open-innovation-to-develop-products-in-cooperation 2024-11-24T15:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/6f1ba5c24e79d6a4/novel-p53-mdm2-inhibitor-plus-ribociclib-demonstrates-anticancer-activity-in-liposarcoma-subset 2024-11-24T15:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/741030ee5a628319/how-functional-and-genomic-precision-medicine-are-getting-closer-to-matching-each 2024-11-24T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/52760393a83e68f3/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/2a17688c093a8c27/luna-optic-data-support-long-term-benefit-of-ixo-vec-for-wet-amd-hcplive 2024-11-24T14:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/5e7e3a80fa5983d7/breakthrough-in-nmda-receptors-research-could-reshape-depression-treatments-study-suggests 2024-11-24T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/aaf1a52244cbfd85/dr-hansford-on-hrqol-outcomes-with-tovorafenib-in-pediatric-braf-altered-low-grade-glioma 2024-11-24T14:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/251c3e25ffbdca77/dr-gershon-on-deep-responses-with-mirdametinib-in-nf1-pn-onclive 2024-11-24T13:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/87618259681241b4/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-24T13:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/5f8888b282fe5599/the-targeted-pulse-discover-key-fda-actions-in-leukemia-and-nsclc-and-the 2024-11-24T12:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/b8bb83c9af68206f/cerevance-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/180c4fb1360ac231/bios-health-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/a1cfa6e4d2322372/cellcentric-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/fa3ebae2e024557b/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip-yahoo-finance 2024-11-24T11:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/ca4ac16ccb6c11ab/anavex-striving-for-excellence-in-rett-syndrome-trial-rttnews 2024-11-24T10:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/c8348adb56057c69/how-valve-type-anesthesia-strategy-affect-tavr-outcomes-cardiologists-perform-live 2024-11-24T10:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/007d88a4da31471c/bridgebio-pharma-fda-approves-heart-disease-drug-acoramidis-rttnews 2024-11-24T09:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/19f79eb47054dd4b/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-pipelinereview 2024-11-24T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/699a9cef2245723c/tetris-used-as-therapy-to-reduce-ptsd-symptoms-in-pandemic-healthcare-workers 2024-11-24T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/4493ddd8e6b4ce85/meta-analysis-supports-potential-use-of-ketamine-for-ptsd-ocd-hcplive 2024-11-24T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/801282bd259b3e54/revolutionary-drug-approvals-and-global-health-updates-devdiscourse 2024-11-24T08:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/7c3b5ffa662adedd/consent-related-outcomes-in-the-alteplase-compared-to-tenecteplase-trial-pubmed 2024-11-24T07:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/b876d5f91e37db94/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-msn 2024-11-24T06:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/0f5fe5c9c31ca23e/breakthrough-treatment-cures-rare-deadly-skin-disease-for-1st-time-newsbytes 2024-11-24T06:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/f956814c2e489a57/ai-model-predicts-risk-of-post-operative-afib-cerebral-protection-devices-tavr 2024-11-24T06:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/99de9663ceeb68d3/researchers-call-for-inclusive-cancer-trials-and-treatments-to-address-an-overlooked-source 2024-11-24T05:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/805b2827e0a6880b/humacyte-inc-shareholder-alert-robbins-llp-reminds-globenewswire 2024-11-24T05:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/98982efe1e3e3938/fda-s-ai-medical-device-regulation-gap-raises-safety-concerns-as-healthcare-ai-adoption-accelerates 2024-11-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/18530ec388299c7d/probiotics-shown-to-mitigate-effects-of-toxic-fire-retardant-chemicals-news-medical 2024-11-24T03:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/42dc81f34683853c/diet-quality-body-weight-and-postmenopausal-hot-flashes-a-secondary-analysis-of-a 2024-11-24T03:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/8dc729e3c48a5385/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T02:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/de6223c4942d15ec/new-initiative-aims-to-explore-diet-s-role-in-lupus-care-news-medical 2024-11-24T01:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/6b887b697782d9d5/breaking-health-news-fda-approves-drug-for-rare-heart-condition-and-more 2024-11-24T00:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/d94f7361db7c15bb/lipella-pharma-completes-dosing-for-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus 2024-11-24T00:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/b6ae012bd0d65944/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T00:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/d8eda893d4d04645/tango-therapeutics-reports-third-quarter-2024-financial-results-gurufocus 2024-11-24T00:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/2fa860a6f51b7ceb/updated-zanidatamab-data-shows-durable-response-in-biliary-tract-cancer 2024-11-24T00:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/eb3ba7cc9f20445f/u-s-fda-found-asthma-drug-singular-montelukast-impacts-the-brain-reuters-says 2024-11-23T23:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/76902bb1b0f44aee/this-week-in-ophthalmology-week-of-november-18-2024 2024-11-23T23:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/a9c981cb7c00b2a5/dr-harding-on-the-fda-approval-of-zanidatamab-for-her2-biliary-tract-cancer-onclive 2024-11-23T22:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/0c3ce5b5cb0eb5c1/drug-company-deal-delivers-hope-for-dementia-business-scoop 2024-11-23T22:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/79e8bac7a428e7c5/drug-company-deal-delivers-hope-for-dementia-auckland-scoop 2024-11-23T22:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/3cc1d95a3183cd36/behind-the-phase-1-study-of-tar-210-in-fgfr-altered-nmibc-targeted-oncology 2024-11-23T22:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/fe3f1e79c88cb30f/3-reasons-why-buying-madrigal-pharmaceuticals-today-is-a-wise-move-yahoo-finance 2024-11-23T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/c710793b80fa5e7a/vorasidenib-shows-consistent-efficacy-with-manageable-safety-in-idh1-2-mutant-diffuse-glioma 2024-11-23T19:47:58+00:00 weekly 0.7 https://trial.medpath.com/news/b14d3c7bda6e57b7/a-journey-into-the-unknown-with-my-daughter-s-aggressive-brain-cancer-cure-today 2024-11-23T19:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/6e22e62ac3c8d7f7/first-patient-dosed-in-phase-i-iia-clinical-trial-of-abi-110-modern-retina 2024-11-23T19:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/551fd3dea82c5ce9/health-equity-access-weekly-roundup-november-23-2024 2024-11-23T19:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/c5826d51bde4ac50/chinese-scientists-report-promising-results-from-novel-alzheimer-s-surgery-here-s-how 2024-11-23T18:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/240352cad8ce3fd3/govt-launches-india-s-first-indigenous-antibiotic-nafithromycin-indiamedtoday 2024-11-23T18:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/25c6f7cdfcb62d65/viltolarsen-slows-dmd-progression-in-small-study 2024-11-23T18:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/e5680bba46ef6d31/tovorafenib-leads-to-durable-off-treatment-responses-in-pediatric-braf-altered-r-r-low 2024-11-23T18:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/e70c4f8ac230b795/consider-brca-hrd-status-before-deciding-on-a-parp-inhibitor-for-ovarian-cancer 2024-11-23T18:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/4ea750fbbd4106f6/nano2-plus-radiation-temozolomide-is-under-exploration-in-newly-diagnosed-glioblastoma 2024-11-23T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/b25aada8245e3c7f/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-23T17:53:34+00:00 weekly 0.7 https://trial.medpath.com/news/005bcabee5cfcd8d/surprising-link-between-covid-and-cancer-a-potential-breakthrough-health 2024-11-23T17:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/0582ae8dac42c091/belantamab-mafodotin-achieves-secondary-end-point-for-treatment-of-relapsed-refractory 2024-11-23T16:53:52+00:00 weekly 0.7 https://trial.medpath.com/news/78496a92c32fc7f9/j-j-submits-sbla-for-guselkumab-tremfya-subcutaneous-induction-regimen-in-uc 2024-11-23T16:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/564227f4f8584614/what-happened-in-optometry-this-week-november-18-november-22 2024-11-23T16:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/adea69983cb0009d/zenyaku-kogyo-receives-japanese-approval-for-anti-cd20-monoclonal-antibody-rituxan-to 2024-11-23T16:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/95ecd76e32acb61c/social-determinants-drive-disparities-in-pediatric-stem-cell-transplant-outcomes-and-access 2024-11-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0cb6c76f033d6d07/acuitive-technologies-receives-fda-510-k-clearance-of-bioactive-bone-void-filler-healio 2024-11-23T15:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/5d05169d3b5e4f5f/all-news-alzforum 2024-11-23T15:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/578d374c18eb4e91/japan-s-mhlw-grants-expanded-indication-approval-to-gsk-s-rsv-vaccine-arexvy-for-pharmabiz 2024-11-23T15:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/abf0363c2e718e31/over-100-mn-doses-of-russia-s-sputnik-v-covid-19-vaccine-to-be-produced-in-india 2024-11-23T14:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/efabd2176f9bbdc9/the-role-of-the-estimand-framework-in-the-analysis-of-patient-reported-outcomes-in-single-arm-trials 2024-11-23T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/c4882899db542afb/first-fda-approved-retinal-gene-therapy-available-at-mayo-clinic 2024-11-23T14:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/73495260ed6ea111/dr-janjigian-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-11-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/8f5830ab88feb3be/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles 2024-11-23T13:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/b79a1d37d8d1c2d3/rlf-td011-spray-fights-bacteria-aids-wound-healing-phase-1-trial 2024-11-23T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/779de332a19920a6/leads-biolabs-receives-us-fda-orphan-drug-designation-for-anti-pd-l1-4-1bb-bispecific 2024-11-23T12:32:10+00:00 weekly 0.7 https://trial.medpath.com/news/26fdd94e75bef34e/dr-lukas-on-survival-outcomes-with-eflornithine-in-idh-mutant-anaplastic-astrocytoma 2024-11-23T12:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/a87838b2d99729ab/fda-approves-nerivio-for-migraine-treatment-in-children-aged-8-years-and-older 2024-11-23T12:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/d4a2ae6efa30611b/trexbio-84-million-series-b-closed-to-decode-human-tissue-immune-biology 2024-11-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/97037d64006fd3ad/metsera-215-million-series-b-raised-to-develop-medicines-for-obesity-and-metabolic-diseases 2024-11-23T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/67a19d96ce19ffcf/parkinson-agent-solengepras-enters-phase-3-sage-to-discontinue-sage-718-serious 2024-11-23T12:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/980806216702d0f2/chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203-a-biosimilar 2024-11-23T12:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/24ff9dc7e418b313/gsk-announces-japan-s-mhlw-approved-application-to-extend-indication-of-arexvy 2024-11-23T11:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/da60e51cc1d71112/zevra-therapeutics-launches-miplyffa-for-niemann-pick-disease-yahoo-finance 2024-11-23T11:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/fe3128b8ad3eadd8/the-oncfive-top-oncology-articles-for-the-week-of-11-17-onclive 2024-11-23T11:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/e04fb1e5fa53f691/two-firms-aim-to-create-functional-cure-for-type-1-diabetes-the-streetwise-reports 2024-11-23T11:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/6b691bb50b5f9f98/midlothian-gp-practice-champions-clinical-research-healthandcare-scot 2024-11-23T11:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/a7c978393f6266e3/replimune-stock-rallies-on-bla-filing-for-melanoma-combo-drug-yahoo-finance 2024-11-23T10:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/e7a3bcb930e08034/psma-targeted-radiation-drug-for-prostate-cancer-subset-meets-study-goal-cure-today 2024-11-23T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/caae7b47859acc79/fda-accepts-resubmitted-nda-for-ataluren-in-nonsense-duchenne-muscular-dystrophy 2024-11-23T09:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/58811d5ce883bb2e/trials-needed-for-sequencing-checkpoint-inhibitors-in-bladder-cancer-targeted-oncology 2024-11-23T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/5db6abad0735608b/ivig-shows-promise-in-neuroimmune-disorders-with-potential-applications-for-long-covid-treatment 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a861617c9ebfc84e/novel-treatment-strategies-emerge-for-neuroendocrine-tumors-from-surveillance-to-captem-therapy 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6013709a54765257/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-yahoo-finance 2024-11-23T08:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/ce000e158a589509/cgtlive-r-s-weekly-rewind-november-22-2024 2024-11-23T08:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/795ea8fefc3b35d0/violette-trial-shows-precise-planning-in-prostate-cancer-microwave-ablation 2024-11-23T07:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/428075ff140e417d/mri-scans-at-triple-the-speed-and-just-as-sharp-alzforum 2024-11-23T07:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/7083be21c7947181/study-links-tooth-loss-to-increased-risk-of-sleep-apnea-highlighting-dental-sleep-health-connection 2024-11-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddab8936aa35e7fa/intensity-therapeutics-is-establishing-a-new-field-of-localized-cancer-reduction-ceo 2024-11-23T06:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/408963f99154d608/fda-approves-iloperidone-fanapt-r-for-bipolar-i-disorder-open-minds 2024-11-23T06:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/7cf468bbfe7d2de2/breakthrough-medications-show-promise-in-reducing-lipoprotein-a-levels-by-up-to-90 2024-11-23T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a339bc9f96e5fb92/bridgebio-announces-fda-approved-attruby-for-attr-cm-patients-markets-insider 2024-11-23T05:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/0e9126afba4eb705/a-glimpse-of-noncoding-rnas-secondary-structure-emerging-trends-and-potential 2024-11-23T04:53:31+00:00 weekly 0.7 https://trial.medpath.com/news/c9ac866780ac0f37/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer 2024-11-23T04:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/aa250197e98fd00a/advances-in-tnbc-mixed-news-in-lung-cancer-report-pancreatic-cancer-overdiagnosis 2024-11-23T04:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/cd1172a0914787a8/real-world-study-confirms-similar-efficacy-of-guselkumab-and-il-17i-for-psa-hcplive 2024-11-23T04:27:56+00:00 weekly 0.7 https://trial.medpath.com/news/7ef9ff4f15f2694c/the-big-give-christmas-challenge-2024-cure-parkinson-s 2024-11-23T04:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/3ca8151d411d2965/nuanced-and-far-reaching-effects-of-gamma-secretase-inhibition-in-the-multiple-myeloma-patients 2024-11-23T03:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/8de8ddfc35cad32f/launch-of-the-lola-project-for-the-non-invasive-detection-of-lung-and-colon-cancer-ibs-granada 2024-11-23T03:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/8ecc688725f76584/treatment-of-oligometastatic-egfr-mutant-lung-cancer-medpage-today 2024-11-23T03:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/7b01044372889847/energy-transfer-and-sunoco-donate-2-million-to-support-pediatric-cancer-research-at-md-anderson 2024-11-23T03:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/124af56030caa6d2/health-canada-issues-noc-to-j-j-s-carvykti-pharmaceutical-technology 2024-11-23T03:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/aa5b0d34ee3b3480/the-beyer-family-skin-cancer-prevention-and-control-initiative-inventum 2024-11-23T02:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/7e3c850db8af0940/fda-approves-acoramidis-bridgebio-s-new-attr-cm-drug-cardiovascular-business 2024-11-23T02:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/390584391a852938/fda-clears-drug-for-rare-and-deadly-gi-cancer-developed-by-canadian-firm-zymeworks 2024-11-23T02:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/81409ebb992ed724/fda-approves-acoramidis-attruby-for-attr-cm-hcplive 2024-11-23T01:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/3badd27845d478cf/scientists-find-disease-causing-bug-could-fight-cancer-surrey-live 2024-11-23T01:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/6dde5a5c3146532f/while-legalizing-marijuana-is-in-limbo-fda-clears-a-ptsd-study-that-could-boost-cannabis 2024-11-23T01:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/70aceaadaaa1fd9a/perrigo-gets-fda-approval-for-store-brand-otc-equivalent-of-nexium-24hr-rttnews 2024-11-23T01:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/ca925548d7ef4253/patient-death-in-rett-syndrome-trial-forces-neurogene-to-drop-high-dose-arm-biospace 2024-11-23T00:42:37+00:00 weekly 0.7 https://trial.medpath.com/news/93292d0496fb13bc/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce 2024-11-23T00:27:07+00:00 weekly 0.7 https://trial.medpath.com/news/ea9eedb81b3097fc/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-biopharma-dive 2024-11-23T00:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/c48ee1c41c5007a1/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/2ac3899966745ddd/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/e035bd3e70b5cb17/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-globenewswire 2024-11-23T00:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/95ece991aba20638/bridgebio-s-attruby-wins-fda-approval-42-reduction-in-attr-cm-mortality-hospitalizations 2024-11-23T00:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/d29bebad63cd7b49/ai-designed-drug-ism5939-granted-ind-clearance-for-cancer-clinical-trials-news-medical 2024-11-22T23:34:48+00:00 weekly 0.7 https://trial.medpath.com/news/c0d71198945cd775/fda-s-drug-review-gold-standard 2024-11-22T23:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/f4d460032f536e0f/ac-immune-q3-2024-strong-progress-and-financial-turnaround-markets-insider 2024-11-22T23:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/bac05b9bec55fd58/promising-outlook-for-crinetics-pharmaceuticals-paltusotine-in-phase-3-trial-drives-buy-rating 2024-11-22T23:25:05+00:00 weekly 0.7 https://trial.medpath.com/news/f1e71f04e03ee7f9/korro-secures-approvals-in-australia-to-commence-aatd-trial-of-krro-110 2024-11-22T23:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/7ed26a8dac783aea/pharma-pulse-11-22-24-challenges-facing-the-pharma-industry-in-2025-more 2024-11-22T23:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/7a159e1c17ad1c24/bioretec-signs-new-distro-deal-for-biodegradable-orthopedic-implants-in-the-u-s 2024-11-22T23:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/e5335fbac7ec3683/gildeuretinol-for-stargardt-secures-fda-rare-pediatric-fast-track-status-hcplive 2024-11-22T23:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/34ba8e9f202672a9/fda-grants-orphan-drug-designation-to-rag-21-for-treatment-of-als-pharmacy-times 2024-11-22T22:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/5eb47d6dbd0619c8/fda-approves-trial-investigating-medical-cannabis-as-ptsd-treatment-for-veterans 2024-11-22T22:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/da406325c2158cd4/fda-approves-attruby-acoramidis-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-patients-with-attr-cm 2024-11-22T22:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/96adf2a45013e7c6/oral-solution-approved-by-the-fda-for-canine-heart-failure-dvm360 2024-11-22T22:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/c50220e92b3f1f5f/ultromics-ai-software-for-cardiac-amyloidosis-gets-fda-approval-bioworld 2024-11-22T22:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/9d5a38b35e7c8eb4/medtronic-receives-key-fda-clearance-launches-new-diabetes-system 2024-11-22T21:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/d6019d446af5ae40/pharma-stock-roundup-eu-nod-for-pfe-s-hympavzi-nvs-ups-sales-view-yahoo-finance 2024-11-22T21:51:33+00:00 weekly 0.7 https://trial.medpath.com/news/53a205bdeb0a3720/nih-new-trialgpt-tool-accelerates-research-by-matching-patients-to-trials 2024-11-22T21:46:31+00:00 weekly 0.7 https://trial.medpath.com/news/a5cc34716680b6a4/accelerated-approval-sought-for-rp1-plus-nivolumab-in-advanced-melanoma-onclive 2024-11-22T21:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/da5d2c8d34be27be/fda-issues-crl-to-avacincaptad-pegol-snda-for-geographic-atrophy-hcplive 2024-11-22T21:36:37+00:00 weekly 0.7 https://trial.medpath.com/news/e63d764bcf905de5/lexicon-to-disband-sales-team-lay-off-60-of-staff-biopharma-dive 2024-11-22T21:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/6b2df49754f81d99/ajmc-r-in-the-press-november-22-2024 2024-11-22T21:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/b97ff12d4003f8ba/category-1-recommendation-of-ribociclib-plus-an-ai-represents-huge-advancement-in-onclive 2024-11-22T21:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/ed9ebeec6b250a3c/dr-garmezy-on-findings-from-the-duravelo-1-trial-in-metastatic-urothelial-carcinoma 2024-11-22T21:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/3b2a1ed80449bca5/fda-accepts-new-drug-application-to-darolutamide-plus-adp-for-mhspc 2024-11-22T20:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/8ec034c8f79eeb1d/marcelo-kugelmas-md-elafibranor-iqirvo-does-not-impact-renal-function-in-pbc 2024-11-22T20:27:41+00:00 weekly 0.7 https://trial.medpath.com/news/819f1dbbf44036f4/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-jd-supra 2024-11-22T20:13:51+00:00 weekly 0.7 https://trial.medpath.com/news/c61858505860cf54/researchers-seek-volunteers-for-clinical-trials-on-health-improvement-local-12 2024-11-22T19:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/8b98304516810108/lack-of-clinical-benefit-of-andexanet-flummoxes-fda-panel-medpage-today 2024-11-22T19:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/8285243924983c19/beyond-antibodies-from-ctad-new-attempts-at-outflanking-alzheimer-s-alzforum 2024-11-22T19:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/ad7a4e078519c907/german-biotech-co-to-relocate-to-houston-thanks-to-4-75m-cprit-grant-innovationmap 2024-11-22T19:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/91b8ce0de1d40580/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/81fcedea0c2d48de/t-dxd-in-her2-overexpressing-and-her2-mutated-nsclc-clinical-trial-data-and-insights 2024-11-22T19:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/ca0060752e90ca14/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/bd3a42b206a203a9/long-term-findings-solidify-role-of-her2-targeted-therapy-in-early-her2-breast-cancer 2024-11-22T19:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/c8e45722732e2197/pragmatic-randomized-trial-of-smartphone-based-nudges-to-reduce-distracted-driving 2024-11-22T19:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1a013e284ed6729/jnj-seeks-fda-approval-of-subcutaneous-induction-regimen-of-tremfya-markets-insider 2024-11-22T19:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/7d76e8dccdbca651/comparison-of-safety-profiles-for-dapagliflozin-based-on-ema-and-fda-safety-issues-plos 2024-11-22T18:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/56c092f99166dbd4/penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-carcinoma 2024-11-22T18:44:12+00:00 weekly 0.7 https://trial.medpath.com/news/1469fc4341e5692d/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T18:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/08bfcef355bc1e91/global-adaptive-platform-trial-for-glioblastoma-to-evaluate-novel-atm-kinase-inhibitor 2024-11-22T18:36:33+00:00 weekly 0.7 https://trial.medpath.com/news/794ddcddea235955/pfizer-s-hympavzi-receives-ec-approval-to-treat-haemophilia-a-and-b-patients-pmlive 2024-11-22T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/news/9872a58d6fdd2016/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of-biospace 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/126fdee860b95843/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/a3e2f4ad70be0faf/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of-biospace 2024-11-22T18:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/2b82b283fbd773af/study-reveals-potential-breakthrough-in-treatment-of-ovarian-cancer-patients-microbiology 2024-11-22T18:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/d44e79c7b41a467d/medtronic-nets-fda-nod-for-smart-insulin-pen-app-medtech-dive 2024-11-22T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/96df7df8bfd8024d/fda-approves-new-targeted-treatment-for-biliary-tract-cancer-webmd 2024-11-22T18:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/78947d44e0711309/arrowhead-pharmaceuticals-submits-fda-application-for-plozasiran-in-familial-pharmacy-times 2024-11-22T18:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/736b1136fd9530d1/tnbc-vaccine-shows-promising-safety-immune-response-in-phase-1-trial 2024-11-22T18:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/03b25aca8e701662/neuralink-receives-health-canada-approval-to-launch-trial-of-implantable-device 2024-11-22T18:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/68ac3986630fd74b/fda-assigns-btd-and-receives-bla-for-rp1-combo-in-advanced-melanoma 2024-11-22T18:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/51822fd98ebf0118/nmpa-approves-belzutifan-for-vhl-in-rcc-cns-hemangioblastomas-or-pnets-onclive 2024-11-22T17:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/fae8d7ac4d2a34cf/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/80573cd04a680429/year-in-review-inflammatory-bowel-disease-medpage-today 2024-11-22T17:52:30+00:00 weekly 0.7 https://trial.medpath.com/news/ff2eff5d7bd286b6/new-attr-cm-drug-linked-to-positive-long-term-data-as-fda-nears-final-decision 2024-11-22T17:46:11+00:00 weekly 0.7 https://trial.medpath.com/news/c01585b4950bab3f/fda-approves-clinical-trial-into-cannabis-as-a-treatment-for-ptsd-following-a-3-year-block 2024-11-22T17:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/96785f9beeb8e0c8/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/3daecb6b595ddbe6/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/7e360de8f7427975/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis-yahoo-finance 2024-11-22T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/news/4aa111a0bbd21784/patient-dies-in-gene-therapy-trial-but-fda-permits-neurogene-to-proceed-with-low-dose 2024-11-22T17:27:36+00:00 weekly 0.7 https://trial.medpath.com/news/9f91d9120afb39b9/penser-reiterates-fair-value-for-diamyd-medical-after-recruitment-milestone-marketscreener 2024-11-22T17:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/e7c7c1bde063ec6e/gildeuretinol-for-stargardt-disease-receives-rare-pediatric-disease-fast-track-designations 2024-11-22T17:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/143ca5610c36448e/quince-hits-new-high-on-nasdaq-phase-3-neat-trial-of-erydex-for-a-t-to-close 2024-11-22T17:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/3cf0e5c21626281b/fda-grants-breakthrough-therapy-designation-to-rp1-plus-nivolumab-in-advanced-melanoma 2024-11-22T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/8b3182b8c90fbde4/alzheimer-s-wonder-drugs-may-shrink-your-brain-should-we-be-worried-science-news 2024-11-22T16:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/a2e6d09134687c12/insud-pharma-receives-2-7m-gates-foundation-grant-to-develop-sublingual-oxytocin-for 2024-11-22T16:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/22d1e7e51836a5d8/johnson-johnson-seeks-fda-approval-for-subcutaneous-tremfya-regimen-for-ulcerative-colitis 2024-11-22T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/826baad2ee4aa2de/using-somatic-cell-genome-editing-to-investigate-treatments-for-hearing-loss-inventum 2024-11-22T16:49:13+00:00 weekly 0.7 https://trial.medpath.com/news/d782fe46668d8dcf/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T16:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/5a7858ce6cad989f/estevan-s-cf-community-celebrates-trikafta-expansion-as-a-major-breakthrough 2024-11-22T16:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/bac6b88a30f7052f/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis 2024-11-22T16:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/4e32574a7a637fdd/perioperative-toripalimab-in-locoregionally-advanced-nasopharyngeal-carcinoma 2024-11-22T16:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/d1b9fd3cf358505f/cardiol-therapeutics-secures-buy-rating-amid-promising-trial-results-webdisclosure 2024-11-22T16:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/8dad42df684767a1/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-yahoo-finance 2024-11-22T16:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/5419749b6bac747c/addition-of-hyperthermic-intraperitoneal-chemotherapy-to-surgery-for-recurrent-ovarian-cancer 2024-11-22T16:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/4477f86ed805a36a/updated-guidelines-for-cpr-following-drowning-former-state-senator-defrauds-hrsa-to-pay 2024-11-22T16:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/c0d16cf51722b178/fda-oks-new-drug-label-for-fludarabine-phosphate-for-cll-treatment 2024-11-22T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/a9a959e3231b6e73/combination-of-eflornithine-and-lomustine-demonstrates-globenewswire 2024-11-22T16:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/ac506d75f1a2ae09/new-alzheimer-s-drug-provides-hope-to-patients-and-families-abc7ny 2024-11-22T15:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/97bcd2271c3db274/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-clinical-trials-arena 2024-11-22T15:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/b44b68b172458369/halozyme-drops-evotec-buyout-bid-patient-dies-in-neurogene-trial-biopharma-dive 2024-11-22T15:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/02dc26fbff6eafac/iv-and-opioid-free-cataract-surgery-sedation-tablet-shows-positive-phase-3-results-healio 2024-11-22T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/bea2fdb8a6ee64a1/kura-oncology-kyowa-kirin-ink-global-strategic-collaboration-to-develop-and-pharmabiz 2024-11-22T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/eccd095e9bb80c5d/jazz-gets-first-fda-nod-for-her2-bispecific-ziihera-pharmaphorum 2024-11-22T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/5f7c8d7fe61452cd/fda-s-historic-approval-of-ptsd-study-may-boost-cannabis-sector-down-the-road 2024-11-22T15:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/75fc65b5f8b59015/piper-sandler-confident-in-keros-stock-sees-potential-ahead-of-phase-ii-data-in-2025 2024-11-22T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/fd69c6c81c51a511/two-in-vitro-studies-on-eravacycline-xerava-r-presented-at-idweek-demonstrating-its 2024-11-22T15:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/a07ef7d2c6dd8946/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/3524f4a477cbf16e/adding-an-hpk1-inhibitor-to-immune-checkpoint-inhibition-may-be-effective-in-solid-tumors 2024-11-22T15:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/62135d95ec2226a6/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/aaf0bb00501b4d3b/tiziana-wins-funding-for-small-clinical-trial-in-als-of-intranasal-foralumab-als-news-today 2024-11-22T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/d76cf74e318848bf/humacyte-sees-success-in-dual-emergency-engineered-tissue-trials-clinical-trials-arena 2024-11-22T14:55:05+00:00 weekly 0.7 https://trial.medpath.com/news/29ed02ba143755c6/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-biospace 2024-11-22T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/7fd4ff893051a2c0/akeso-s-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-biospace 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/b226c73d1fcb6795/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/1365f87f056eaa70/fda-grants-rare-pediatric-disease-fast-track-designations-to-gildeuretinol-for-stargardt 2024-11-22T14:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/84d472de737d46e1/how-an-aha-moment-sparked-a-breakthrough-for-car-t-in-lbcl-stat-news 2024-11-22T14:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/219ca652d4fe7129/promising-steps-to-hiv-vaccine-trump-tariffs-threaten-chinese-profits-5-biotech-stories 2024-11-22T14:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/594611e65d777a3f/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T14:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/40cddd0816832dda/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-pr-newswire 2024-11-22T14:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/6ab95043fddc7484/first-line-systemic-treatment-for-initially-unresectable-colorectal-liver-metastases-jama-network 2024-11-22T13:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/7e1f23b3c1a65588/enveda-therapeutics-gets-a-130m-boost-toward-eczema-treatment-autogpt 2024-11-22T13:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/64dc074be026cfcd/phase-ii-of-chelsea-s-wellbeing-initiative-a-research-practice-partnership-boston-college 2024-11-22T13:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/aeffd924b7eeb401/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/09e7fa54bb055a59/face-to-face-huntington-s-disease-families-are-heard-by-the-fda-hdbuzz 2024-11-22T13:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/600b5200d1e3176b/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/d03d814161910143/enrollment-goal-met-in-phase-3-solar-recur-trial-urology-times 2024-11-22T13:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/6b5376d8bf0173e4/savara-to-present-phase-3-trial-results-for-breakthrough-apap-treatment-at-bts-meeting 2024-11-22T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/1bfcfe0269f71e92/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of 2024-11-22T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/179be85c48bd52c9/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/3eb5530f96dd0798/non-alcoholic-steatohepatitis-nash-treatment-market-2032-clinical-trials-medication 2024-11-22T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/6ec5ffa95113ed1f/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/15171884480cc243/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/30427a64926c5a37/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-pr-newswire 2024-11-22T13:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/41a65feb7dffb7df/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T13:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/127e879b3e8a4386/jazz-secures-fda-nod-for-ziihera-to-treat-her2-positive-btc 2024-11-22T13:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/3c87f05aea8e4dae/astrazeneca-fends-off-adcomm-s-safety-concerns-on-andexxa-axes-mid-stage-opioid 2024-11-22T12:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/8ae23104226054f2/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector 2024-11-22T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/eb5994fbacdb333c/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector-yahoo-finance 2024-11-22T12:36:33+00:00 weekly 0.7 https://trial.medpath.com/news/2d21345dcbbf1744/jiangsu-hansoh-adc-hs-20093-holds-potential-to-set-new-standard-in-sclc-second-line 2024-11-22T12:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/e5d26f4f5774fca6/mayo-clinic-researchers-uses-exome-sequencing-to-identify-individuals-at-risk-of 2024-11-22T12:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/82040332a2f39de3/cinclus-pharma-agrees-on-pediatric-study-plan-with-fda-placera 2024-11-22T12:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/f88ed05bedec6aab/global-cell-and-gene-therapy-trials-driving-innovation-in-oncology-and-beyond 2024-11-22T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/86acacd6acc7abb9/hepa-air-purifiers-show-limited-impact-on-rsv-and-respiratory-infections-in-aged-care-facilities 2024-11-22T12:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/cd64557688fdc010/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/21c99e67f4083a3b/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/b518cd01ae29c3aa/deprescribing-anticholinergics-to-preserve-brain-health-reducing-the-risk-of-dementia-trials 2024-11-22T11:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/b63accd23708bdc7/open-label-study-finds-aficamten-could-help-most-ohcm-patients-avoid-surgery 2024-11-22T11:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/0278671ac5aa4670/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-bispecific 2024-11-22T11:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/b550281683f70c84/lipid-nanoparticle-mediated-mrna-delivery-to-cd34-cells-in-rhesus-monkeys-nature 2024-11-22T11:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/c7033498deec16ec/short-term-hormone-therapy-for-menopause-won-t-harm-women-s-brains 2024-11-22T11:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/6cb0cdbf54ebbc8b/could-a-vitamin-be-effective-treatment-for-copd 2024-11-22T11:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/31c6f54f2992fc9f/hutchmed-china-ltd-fruzaqla-r-launched-in-japan-by-takeda-research-tree 2024-11-22T10:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/44ca679096630a55/evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r-multiple-myeloma-cgtlive-r 2024-11-22T10:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/58cd24e89b798068/research-assesses-feasibility-of-collaborative-clinical-trials-between-health-tech-providers 2024-11-22T10:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/a2d776792be57826/claudin-18-2-targeted-therapy-market-forecast-clinical-globenewswire 2024-11-22T09:58:23+00:00 weekly 0.7 https://trial.medpath.com/news/0df2aac84dbfd488/merck-s-multi-billion-dollar-keytruda-levels-up-with-novel-subcutaneous-delivery 2024-11-22T09:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/530d9e5fed6bf53b/amneal-s-fda-win-exenatide-approval-novel-migraine-autoinjector-resubmission-stock-titan 2024-11-22T09:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/bdd268ca77282dc0/replimune-receives-breakthrough-therapy-designation-for-rp1-globenewswire 2024-11-22T09:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/b94f85aac6775132/uk-pioneers-point-of-care-manufacturing-framework-for-cell-therapies-with-2025-implementation-target 2024-11-22T08:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/ef07a4c1088953f1/fda-updates-fludarabine-phosphate-labeling-in-chronic-lymphocytic-leukemia 2024-11-22T08:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/442c942fc151d7f5/fda-accepts-snda-for-darolutamide-adt-in-hormone-sensitive-prostate-cancer 2024-11-22T08:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/cb8c1757ca1549d4/abbisko-cayman-launches-phase-ii-cancer-drug-trial-markets-insider 2024-11-22T08:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/6ffb73ece5c17fb1/improving-outcomes-using-ribociclib-in-high-risk-node-negative-breast-cancer 2024-11-22T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/a58858c8a990427d/fgfr-altered-nmibc-treatment-advances-with-tar-210-findings-targeted-oncology 2024-11-22T08:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/feacd248bdf372ee/fda-accepts-snda-for-darolutamide-with-adt-for-patients-with-mhspc-pharmacy-times 2024-11-22T07:38:33+00:00 weekly 0.7 https://trial.medpath.com/news/ca9246ea0c885817/effect-of-a-patient-health-engagement-phe-model-on-rehabilitation-participation-in-patients-trials 2024-11-22T07:34:28+00:00 weekly 0.7 https://trial.medpath.com/news/75e76eddb818e24f/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-22T07:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/6d1707c425145b88/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-sustained-growth 2024-11-22T07:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/6404d9e60a513109/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T07:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/a0193b4b24019917/new-grant-aims-to-improve-research-and-trials-for-veterans-health-va-gov 2024-11-22T07:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/37a8b71943302f5f/neuracle-genetics-ng101-receives-fda-fast-track-designation-and-completes-dosing-for 2024-11-22T06:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/1d743c72ade0b3c2/clinical-safety-data-show-switching-between-rituximab-biosimilars-does-not-increase 2024-11-22T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/dc10766918737ac4/the-latest-in-clostridioides-difficile-research-and-news-contagion-live 2024-11-22T05:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/bf96fa70b22636b0/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T04:32:30+00:00 weekly 0.7 https://trial.medpath.com/news/faeb8ceb6b161eb1/trial-tests-focused-ultrasound-to-battle-melanoma-uva-health-newsroom 2024-11-22T04:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/3a0de0c653a2ef3a/us-fda-approves-jazz-pharma-s-ziihera-to-treat-adults-with-previously-treated-unresectable 2024-11-22T04:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/799a884257bad5b1/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-22T04:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/6b0bb7f6310551a9/dapirolizumab-pegol-seen-to-reduce-sle-disease-activity-in-phase-3-trial 2024-11-22T04:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/419c756ae52fc52a/abbisko-cayman-launches-phase-ii-cancer-drug-trial-tipranks-com 2024-11-22T04:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/85f299278bb6ca9f/fda-approves-cancer-drug-developed-by-b-c-s-zymeworks-delta-optimist 2024-11-22T04:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/ab076e057aed2325/zymeworks-jazz-pharmaceuticals-announce-fda-approval-of-ziihera-markets-insider 2024-11-22T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/8f58e4008823223d/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug-outsourcing-pharma-com 2024-11-22T03:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/49203f09021274ec/new-stomach-cancer-drug-vyloy-faces-access-challenges-despite-approval-kbr 2024-11-22T02:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/ab138f062afae3e7/ui-researchers-receive-funding-for-clinical-trials-in-new-cancer-treatment-the-daily-iowan 2024-11-22T02:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/041aefc2df8f91f2/immunitybio-partners-with-ncartes-to-streamline-clinical-trial-data-collection-through-emr-automation 2024-11-22T01:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/70f5990ee250f31d/first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv 2024-11-22T01:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/438311136f84d931/neoadjuvant-oncolytic-virus-orienx010-and-toripalimab-in-resectable-acral-melanoma-a-phase-ib-trial 2024-11-22T01:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/ababa3785adbdf39/ipsell-is-a-biotechnology-company-that-specializes-in-using-induced-pluripotent-stem-cells-to-produc 2024-11-22T01:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/a84e836ca37c5ff9/new-neuroimaging-marker-may-identify-persons-at-risk-of-dementia-in-future-clinical-trials 2024-11-22T01:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/e6fa842b213b0bab/ocugen-secures-ema-orphan-designation-for-ocu410st-advancing-stargardt-disease-treatment 2024-11-22T01:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/b9fb07bee0d53614/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-the-national-law-review 2024-11-22T00:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/1a483ec348a955ad/bioadaptives-plans-5-new-products-zeranovia-weight-management-drug-shows-promise 2024-11-22T00:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/8ef5df56290de1d5/umdf-and-khondrion-announce-the-mito-fund-s-investment-in-globenewswire 2024-11-22T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/2897d7b9707ec778/b-c-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-business-in-vancouver 2024-11-21T23:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/697d6a5a0f4ef77d/fda-approves-insightec-exablate-prime-for-use-on-philips-systems-massdevice 2024-11-21T23:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/55e09b73c8c97e52/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/321eb984878b8f9b/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/27834e6f284d608b/ich-embraces-innovation-in-clinical-trial-design-citeline 2024-11-21T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/7b1c4e904d22c300/fda-approves-biliary-tract-cancer-treatment-from-jazz-bioworld 2024-11-21T22:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/e240c54c39158335/amneal-resubmits-new-drug-application-for-migraine-treatment-diabetes-drug-is-approved 2024-11-21T22:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/44f3849df691a648/pompe-disease-pipeline-insight-2024-with-comprehensive-globenewswire 2024-11-21T22:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/d62d6f1d355dc4e4/subcutaneous-keytruda-plus-berahyaluronidase-alfa-combo-meets-phase-3-trial-end 2024-11-21T22:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/a46e235aca035230/nivolumab-avd-improves-progression-free-survival-in-advanced-stage-hodgkin-lymphoma 2024-11-21T22:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/d4df34ff246df162/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-gurufocus 2024-11-21T22:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/9ca9d13c0f3f2758/zevra-launches-first-fda-approved-npc-treatment-investing-com 2024-11-21T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/b4837919b9bf18dd/fda-approvals-biliary-tract-cancer-antibody-treatment-managed-healthcare-executive 2024-11-21T21:43:33+00:00 weekly 0.7 https://trial.medpath.com/news/5f12ad9ba5d0fcbb/alzheimer-s-research-participant-finds-hope-in-helping-others-banner-health 2024-11-21T21:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/f488b0cbcee45040/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-targeted-oncology 2024-11-21T21:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/771543ef62ef78a3/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-usa-today 2024-11-21T21:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/efb7df835b96df8b/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T21:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/f984333d9ea2df07/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-21T21:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/29330e0ca1d11fee/phase-3-trials-of-treatment-combo-for-hepatitis-d-expected-in-2025-liver-disease-news 2024-11-21T21:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/f32276ef59a70bb2/replimune-seeks-fda-approval-for-breakthrough-melanoma-treatment-rp1-stock-titan 2024-11-21T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/d31f8ec112685ea2/new-publication-from-the-undiagnosed-pediatric-patients-team-fakultni-nemocnice-brno 2024-11-21T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/7323a49126baa6b6/zymeworks-inc-announces-fda-accelerated-approval-of-ziihera-r-for-her2-positive 2024-11-21T21:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/6713834b5f7a98ae/clinical-trial-to-address-burnout-enroll-your-practice 2024-11-21T21:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/48ee64a66d6e9b29/r-pharm-reported-phase-iii-trial-results-of-pembrolizumab-gxp-news 2024-11-21T20:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/762722bdc6d97540/rare-milestone-for-canadian-biotech-as-zymeworks-developed-drug-gets-fda-approval 2024-11-21T20:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/22b197e5cc02a1e8/fda-approves-zanidatamab-hrii-for-her2-biliary-tract-cancer 2024-11-21T20:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/600be8036081cd46/fda-approves-zanidatamab-in-her2-biliary-tract-cancer-targeted-oncology 2024-11-21T20:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/18e694cb23a00a77/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm 2024-11-21T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/face51ec2d850846/immunotherapy-for-head-and-neck-cancer-british-dental-journal-nature 2024-11-21T19:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/d418a6d46a34e15b/rallybio-announces-initiation-of-phase-2-clinical-trial-of-rlyb212-biospace 2024-11-21T19:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/925811c2b6e56dec/elon-musk-s-neuralink-green-lit-for-first-brain-chip-trial-outside-us-newsweek 2024-11-21T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/c337912256eabddd/md-anderson-helps-survivor-through-three-cancer-diagnoses 2024-11-21T19:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/e213975268c6e027/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable 2024-11-21T18:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/35b0dd02e5cb7e17/diamyd-medical-ab-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial 2024-11-21T18:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/cd53fae1ea66eaff/weed-for-ptsd-eager-for-better-cannabis-science-f-d-a-clears-study 2024-11-21T18:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/618e3ddd6e3cf187/in-brief-polarean-imaging-gets-fda-approval-for-mri-chest-coil-morningstar 2024-11-21T18:39:57+00:00 weekly 0.7 https://trial.medpath.com/news/8212f1bcbf73b269/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer-yahoo-finance 2024-11-21T18:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/ee5860877b8001ec/fda-approves-zanidatamab-for-biliary-tract-cancer-medpage-today 2024-11-21T18:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/9c59033427bb553c/md-anderson-research-highlights-for-november-21-2024 2024-11-21T18:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/59af6a2dcffffdb2/what-s-next-for-the-psychedelics-regulatory-and-clinical-landscape 2024-11-21T18:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/0fccca860313ab78/kura-oncology-gets-330m-to-kick-off-global-leukemia-drug-pact-with-kyowa-kirin 2024-11-21T18:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/bd68b342c5700709/fda-approves-bimzelx-for-hidradenitis-suppurativa-webmd 2024-11-21T17:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/5a64f41d5284b340/some-alzheimer-s-blood-tests-are-racing-toward-ivd-certification-alzforum 2024-11-21T17:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/193998eddcf3cbf9/pbyi-begins-phase-ii-study-on-alisertib-combo-in-breast-cancer-barchart-com 2024-11-21T17:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/7ad88e870a9f7979/soft-launch-of-first-indigenous-antibiotic-to-combat-amr-nafithromycin-announced-by-dr 2024-11-21T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/62a0a299d7e49b4c/laparoscopic-cytoreduction-after-neoadjuvant-chemotherapy-in-high-grade-jama-network 2024-11-21T17:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/61686134a27e142d/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-yahoo-finance 2024-11-21T17:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/239c554a0869978c/elon-musk-s-neuralink-gets-first-ever-approval-outside-of-u-s-teslarati 2024-11-21T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/4f5c605f63c28a04/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/e86bc1e74964a450/md-anderson-research-highlights-for-november-21-2024-newswise 2024-11-21T17:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/57ec86246799b69c/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:02:33+00:00 weekly 0.7 https://trial.medpath.com/news/92143d9bb4143419/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable-yahoo 2024-11-21T16:59:27+00:00 weekly 0.7 https://trial.medpath.com/news/02523d52a6a97261/offworld-life-science-brain-organoids-grown-in-microgravity-the-astrobiology-web 2024-11-21T16:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/8f8ce2f20b0039ce/antibody-drug-conjugate-targeting-cldn1-receives-fda-fast-track-designation 2024-11-21T16:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/302c57de704f3aa1/ich-embraces-innovation-in-clinical-trial-design-pink-sheet-key-regulatory-and-policy-insights 2024-11-21T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/46c3f6248c79e271/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-clinical-trials-arena 2024-11-21T16:55:03+00:00 weekly 0.7 https://trial.medpath.com/news/4a76aae43c8b6377/intravenous-injections-of-zanidatamab-hrii-receives-fda-accelerated-approval-for-ihc-btc 2024-11-21T16:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/21b9f488692be474/fda-approves-zanidatamab-for-biliary-tract-cancers-with-high-her2-levels 2024-11-21T16:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/bb9a979d01cdd6db/fda-accepts-snda-for-darolutamide-plus-adt-in-metastatic-hormone-sensitive-prostate-cancer 2024-11-21T16:23:35+00:00 weekly 0.7 https://trial.medpath.com/news/674aa866ac3633ea/expanded-cancer-care-options-translate-to-hope-for-both-urban-rural-patients-siouxfalls-business 2024-11-21T16:19:41+00:00 weekly 0.7 https://trial.medpath.com/news/c94b1a5723c3fcdf/olverembatinib-after-failure-of-tyrosine-kinase-inhibitors-including-ponatinib-or-asciminib 2024-11-21T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/df0bc55b95ab36ae/from-bench-to-bedside-osteoarthritis-gene-therapy-developed-in-the-lab-at-baylor-is-in 2024-11-21T16:15:43+00:00 weekly 0.7 https://trial.medpath.com/news/ef600bf7cfec4572/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T16:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/9200287b8591152a/supira-medical-initiates-u-s-early-feasibility-study-efs-for-high-risk-pci 2024-11-21T16:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/bd3374d92855f8e8/kedrion-s-facility-in-bolognana-approved-by-fda-to-produce-ryplazim-contract-pharma 2024-11-21T16:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/0caf8e2b7e71baf1/efficacy-of-preoperative-prophylactic-application-of-betamethasone-on-postoperative-nausea 2024-11-21T16:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/c5868953eabba090/ai-improves-prediction-of-response-to-pd-l1-inhibitors-in-urothelial-carcinoma 2024-11-21T16:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/463df7308ca3c760/bayer-expands-indications-for-nubeqa-with-new-drug-application-clinical-trials-arena 2024-11-21T16:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/51bfd354ec59f9ba/invikafusp-alfa-shows-potential-in-pd-1-refractory-solid-tumors-targeted-oncology 2024-11-21T16:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/d742e95c789035d6/vir-biotechnology-s-promising-therapeutic-advancements-justify-buy-rating 2024-11-21T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/8b1bd810928767e7/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-the-detroit-news 2024-11-21T15:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/7b635645b9084372/jama-commentary-highlights-need-for-virtual-vigilance-in-decentralized-clinical-trials 2024-11-21T15:24:38+00:00 weekly 0.7 https://trial.medpath.com/news/70d5c5b74a6b2445/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-yahoo-finance 2024-11-21T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/11bd458cd8cc915d/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-msn 2024-11-21T15:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/2a463755a60ca41b/gout-pipeline-research-report-2024-comprehensive-insights 2024-11-21T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/0a300a9985ad2f40/elon-musk-s-neuralink-gets-green-light-for-more-clinical-trials 2024-11-21T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/3fce051a1f099308/fda-grants-accelerated-approval-to-jazz-pharmaceuticals-ziihera-for-her2-positive-biliary 2024-11-21T15:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/48de735d84e2117f/ai-drug-discovery-startup-enveda-raises-130-million-bnn-bloomberg 2024-11-21T15:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/6372a22eb14fa792/neuralink-gets-green-light-to-launch-bci-trial-in-canada-massdevice 2024-11-21T15:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/0f75db67f1c79525/neurosense-therapeutics-to-participate-in-the-2024-international-symposium-on-als-mnd 2024-11-21T15:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/6e28f12069db7ea8/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-urology-times 2024-11-21T14:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/28e8490c98a9a192/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-21T14:51:56+00:00 weekly 0.7 https://trial.medpath.com/news/db88d247fb33061a/emstoptm-announces-completion-of-capture-1-early-feasibility-clinical-trial 2024-11-21T14:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/e80a24e30ef82bb2/dosing-begins-in-phase-3-trial-of-parkinson-s-therapy-solengepras 2024-11-21T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc1457293861cf79/neuralink-gets-approval-to-start-human-trials-in-canada-yahoo-news 2024-11-21T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/524f00ccc82eaf30/new-amsterdam-sees-success-in-phase-iii-cardiovascular-disease-trial 2024-11-21T14:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/70c5d512e7a967c5/anxiety-drug-trials-keep-stifel-optimistic-on-vistagen-stock-s-upside-potential-investing-com 2024-11-21T14:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/f39ee48318a5ca0c/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:27:48+00:00 weekly 0.7 https://trial.medpath.com/news/e06289d8bbc99592/fda-approves-ziihera-for-some-with-biliary-tract-cancer-cure-today 2024-11-21T14:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/ec9028936c3411a5/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial-biospace 2024-11-21T14:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/a35bdc60e8d16017/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/898304cd59311c14/soligenix-launches-european-advisory-board-for-phase-3-hybryte-ctcl-trial 2024-11-21T14:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/e0fcdbf30f1cc87e/fda-approves-zihera-for-advanced-her2-positive-biliary-tract-cancer-healio 2024-11-21T14:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/df296cc6a9dadd64/huntington-s-disease-a-therapeutic-field-on-a-bumpy-ride-labiotech 2024-11-21T14:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/f33c4db09bf44ca1/tune-therapeutics-to-initiate-clinical-trial-of-first-in-class-epigenetic-silencer-in-chronic-hepatitis-b 2024-11-21T14:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/d3b181be4fa74d15/zerlasiran-achieves-durable-lp-a-reductions-at-60-weeks-with-stephen-j-nicholls-md-phd 2024-11-21T14:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/3a0ab4541186ff60/kura-kyowa-kirin-join-forces-to-develop-commercialize-ziftomenib-contract-pharma 2024-11-21T14:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/693a93c5b07d9222/fda-approves-zanidatamab-for-pretreated-her2-positive-biliary-tract-cancer 2024-11-21T13:56:33+00:00 weekly 0.7 https://trial.medpath.com/news/1f0ccb72290a7f9e/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T13:54:15+00:00 weekly 0.7 https://trial.medpath.com/news/c8786ad1c593717e/science-37-delivers-47-us-enrollment-in-gsk-s-phase-3-rare-disease-trial-stock-titan 2024-11-21T13:50:16+00:00 weekly 0.7 https://trial.medpath.com/news/0d2d04423d839306/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T13:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/125c642b74f6cc01/regenxbio-starts-pivotal-clinical-trial-testing-dmd-gene-therapy-rgx-202 2024-11-21T13:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/48338195d7751853/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-morningstar 2024-11-21T13:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/4c43f458205c4316/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-cision-news 2024-11-21T13:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/01076e3e82a7f7b8/life-science-tools-market-projected-to-reach-455-billion-by-2033-growing-at-10-9-cagr 2024-11-21T13:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/41ad8359c214b480/rwjbarnabas-health-expands-access-to-clinical-trials-through-academic-community-partnership 2024-11-21T13:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/dbc36e31d602a2a1/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-biospace 2024-11-21T13:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/d55adef8b2556bf9/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:19:02+00:00 weekly 0.7 https://trial.medpath.com/news/43a3e70a52521e66/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-yahoo-finance 2024-11-21T13:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/760afae26ed603ad/intensity-therapeutics-secures-3-million-in-stock-offering-investing-com 2024-11-21T13:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/932f049326f677b2/diamyd-medical-reaches-recruitment-target-in-phase-3-study-diagnode-3-marketscreener 2024-11-21T13:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/c36e505acf806418/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/5753abb9919c3d9a/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/b7cc28b841b098d4/insightec-secures-fda-approval-and-ce-marking-for-exablate-r-prime-on 2024-11-21T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/f1859fd51bc110e9/newamsterdam-pharma-reports-promising-phase-3-trial-results-yahoo-finance 2024-11-21T12:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/52bcd8f4dd6ac333/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-r-for 2024-11-21T12:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/f25bf35d0b6a913e/thrombocytopenia-treatment-market-2034-clinical-trials-openpr-com 2024-11-21T12:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/7bcece0b35addcc8/perspective-therapeutics-to-pursue-dose-escalation-of-212pb-vmt-a-net-in-its-quantisnow 2024-11-21T12:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/bd55599d85d8f397/elon-musk-s-neuralink-cleared-for-brain-chip-trials-in-canada-financial-post 2024-11-21T12:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/1ba5372827c4a39f/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/131d348f481e829d/marvel-biosciences-secures-300k-grant-for-breakthrough-alzheimer-s-drug-development 2024-11-21T12:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/b0b293ab9850bdf6/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-stock-titan 2024-11-21T12:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/dc1235b3953346fe/keytruda-represents-almost-half-of-merck-s-sales-and-a-new-formulation-could-fend-off-rivals 2024-11-21T12:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/18b372ef64e0de55/interim-report-q3-2024-curasight-cision-news 2024-11-21T12:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/cd9506036129eb57/eu-clinical-trials-regulation-no-536-2014-enhances-harmonization-and-transparency 2024-11-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/82d26b14254518b4/merck-data-at-the-ash-2024-annual-meeting-highlights-promising-hematology-pipeline 2024-11-21T11:51:48+00:00 weekly 0.7 https://trial.medpath.com/news/80cfcb2ab3ea680f/ai-method-can-measure-cancer-severity-using-pathology-reports-to-shorten-selection-process 2024-11-21T11:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/b11bdd4757236626/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-et-healthworld 2024-11-21T11:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/a7ed6b1848efd3ef/melt-reports-topline-outcomes-from-trial-of-melt-300-for-cataract-surgery 2024-11-21T11:25:19+00:00 weekly 0.7 https://trial.medpath.com/news/f40363a17aca3769/lipella-pharmaceuticals-announces-completion-of-first-cohort-in-phase-2a-trial-of-lp-310 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/d097e7c94f2147e7/new-alliance-for-the-development-of-a-sublingual-oxytocin-formulation-to-prevent-biospace 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/8263620762af3742/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:22:10+00:00 weekly 0.7